

Curriculum vitae

Prof Jeannette Lechner-Scott
PhD, FRACP
February 2019



Name:	JEANNETTE LECHNER-SCOTT
Address:	130 Ocean Street Dudley NSW 2290 Australia
Email:	jeannette.lechner-scott@hnehealth.nsw.gov.au
Telephone:	+61 2 49213540
Fax:	+61 2 49213488
Birth date:	04. 04. 65
Nationality:	German
Marital status:	Married to Prof. R.J. Scott
Children:	Maximilian *1998 Lorenz *2001 Lukas *2001
Residency status:	Permanent Resident
NSW Medical registration:	MPO 335963

Medical Qualifications

November 1991	Medical Degree University Heidelberg
June 1993	PhD University of Heidelberg
January 1998	Specialist in Neurology, FMH Germany
August 2003	FRACP

Present Employment

Senior Staff Specialist	Neurology General Medicine John Hunter Hospital Lookout Rd New Lambton Heights NSW 2305
-------------------------	---

University Career

1984-1985	Medical Faculty, University Padova, Italy
1985-1991	Medical Faculty, University Heidelberg, Germany
1987-1992	PhD, Dept. of CNS- Physiology with Prof. Dr. Zimmermann, University Heidelberg, Germany
2004- 2007	Conjoint Lecturer, University Newcastle, Australia

Nov 2007	Conjoint Senior Lecturer University Newcastle, Australia
Nov 2011	Conjoint Associate Professor University of Newcastle
June 2017	Conjoint Professor University of Newcastle

Society and Board Membership

Australasian College of Physicians
Australasian Association of Neurologists
Advisory Board Member for Bayer, Biogen, Genzyme, Merck, Novartis and TEVA
Member of Centre for Information Based Medicine, Hunter Medical Research Institute,
University of Newcastle
Chair of Australian MS Clinical Trials Network
Executive Board member of NSW MS Research & Clinical Trials Network
Member of ANZGene consortium
Medical and Scientific Board of MS Australia
Member of Hunter Medical Post Graduate Institution since 2009
Board Member of Hunter Medical Post Graduate Institution since 2013
Chair of HPMI board since 2017
Member of the Research Management Council of the School for Medicine and Public
Health
Associate Editor Frontiers of Neurology
Editorial Board Member of Translational Medicine & Research
Australian Representative for MSA on the International Medical and Scientific Board.
Member of the ANZAN scientific and program committee
Chief editor for MS and related disorders

Previous Employment

1992-1993	Residency Neurology, University Freiburg, Germany - Pain Clinic - General Neurology
1993-1996	Registrar Neurology, University Hospital, Kantonsspital Basel, Switzerland -General Neurology -MS-clinic -Intensive Care Unit -EEG
1996-1997	Registrar Psychiatric University Clinic Basel Switzerland
1997-1998	Registrar EMG-Department Neurology, University Clinic Basel Switzerland
January 1999 – January 2001	Medical Registrar John Hunter Hospital, Newcastle, Australia Rotations: General Medicine Cardiology Respiratory Haematology Renal Medicine Infectious Disease & Immunology
February 2001 – October 2001	Maternity Leave

October 2001 – January 2002

Medical Registrar
John Hunter Hospital
Newcastle, Australia

January 2002 –November 2002

Medical Registrar
Mater Hospital
Newcastle, Australia

Rotations: General Medicine
Oncology
Haematology

January 2003 – January 2004

Medical Registrar
John Hunter Hospital
Newcastle, Australia

Rotations: Rheumatology
Gastroenterology
Orthogeriatrics

Current Research

Principle Investigator

REFLEX	multicentre international clinical trial with new formula Rebif for early onset MS
DEFINE	mutlicentre international clinical trial with oral treatment with BG12 for RR MS
ATAMS	multicentre international clinical trial with Ataccept for RR MS
TOWER	mutlicentre international clinical trial with oral treatment with Teriflunomide 2 for RR MS

DECIDE multicentre international clinical trial with daclizumab versus Avonex in RR MS

GEMESIS local study investigating the genetic basis of MS

MSBasis epidemiological study of MS patients

MSCOMET observational trial to compare treatments in RR MS

BEGIN multicentre observational study of early onset MS on Betaferon

MusiQoL multicentre international Quality of live study for people with MS

ENABLE multicenter international study with Fampridine in MS

EARLiMS multicentre observational study with oral medication for RRMS

NMO study measuring prevalence and presentation of NMO

TERACLES multicenter international phase III trial for RRMS with Teriflunomide add on to beta-interferon

PREVANZ multicenter Australian phase III trial with Vitamin D in CIS

TOP multicenter international phase IV trial with Natalizumab in RRMS

FLEX phase II study of spicy drink for spasticity in MS

ASCLEPIOS multicenter international phase III trial comparing OFATUMUMAB and teriflunomide

ENSEMBLE phase III/IV study of Ocrelizumab as first line treatment

AFFINITY multicenter international phase III study Add on Opicinumab

POP multicenter international phase IV trial on Plegridy in RRMS

	MEDDAY Effect of MD1003 in progressive multiple sclerosis: a randomized double blind placebo controlled study
	VISIONARY-MS phase 2 study in RRMS for remyelination
Co-Investigator	ANZgene Australian multicentre study to investigate genetic predisposition to MS Wellcome Trust project International study of genome wide association in MS AUSLONG Extension study to Ausimmune
Steering Committee	PrevANZ phase III trial for Vitamin D3 in CIS MSFirst phase IV observational safety study on all treatment for MS via MSBase MAN-CDX phase IV trial for cladribine QoL over 2y
Safety Committee (Chair)	Innate study phase II study with novel product in RR MS
Associated Editor	Frontiers in Neurology
Reviewer for	Expert opinion on biological therapies Multiple Sclerosis Journal Clinical Epigenetics Journal of Neuroimmunology

PhD students

Mathew B Cox	Molecular studies in Multiple Sclerosis Completed September 2013
Moira Graves	Cytokines in fatigue and cognition in Multiple Sclerosis Completed December 2015
Kate Sanders	microRNA changes in brain of MS patients Completed March 2017
Oun Issa Salman	Using Fast spectroscopic imaging sequence to generate metabolic maps of whole brain- Application in MS
Jameen Arm	Magnetic Resonance Spectroscopy (MRS) in the diagnosis and management of Multiple Sclerosis
Kira Groen	miRNA expression in red blood cells and extracellular vesicles in patients with MS
Sean Burnard	Genetic and molecular differences of Multiple Sclerosis subgroups. Is there a failure in viral and aberrant immune cell clearance driving disease course?
Hafiz Rehan Afzal	Using artificial intelligence to determine disease risk of multiple sclerosis on MRI
Abdulaziz M. Alsheri	DTI analysis of multiple sclerosis scans over time

Honours Students

Samara Bray	miRNA expression in MS brains Completed June 2017
-------------	--

Master Students

Susan Agland	<u>M</u> indfully Managing <u>S</u> tress in Multiple Sclerosis (MindS) Completed December 2017
--------------	--

Research Grants

Current support

Funding Agency: Jhh Charitable Trust account

Project Title: "How can MRI be used to evaluate Fatigue and depression in MS patients?"

Name of investigators: J. Lechner-Scott, S. Ramadan, V. Maltby

Value of support: \$20,063

Year 2019-2020

Funding Agency: MS Research Australia 18-0424

Project title: Identifying changes in genome-wide DNA methylation associated with MS onset and severity.

Name of investigators: R. Scott, J. Lechner-Scott, V. Jokubaitis, M. Slee, R. Lea

Value of support: \$211,000

Funding year: 2019-2021

Funding Agency: NHMRC

Project title: [Multiple Sclerosis: Pregnancy and Prognosis](#)

Name of Investigators: V. Joukbaitis, A. Van der Walt, P. Mc Combe, K. Hellwig, J. Stankovic, J. Lechner-Scott

Value of support: \$470,078.80

Funding year:2019-2022.

Funding Agency: Merck

Project title: Cladribine: Longitudinal Observational Biomarker Australian Study

Name of Investigators: J. Lechner-Scott, V. Maltby, H. Butzkueven, B. Taylor, P. McCombe, ,,,,

Value of support: \$ 3,425, 653

Funding year: 2019-2028

Funding Agency: APP1152317- NHMRC 2018 Medical Research Future Fund

Project title: A randomised placebo-controlled trial of combined mitochondrial agents for the treatment of fatigue and depression in multiple sclerosis with an assessment of the impact on kynurenine pathway metabolomics.

Name of Investigators: Ponsonby A-L, Lucas R, Taylor B, nan der Mei I, Jacka F, Fernandes B, Broadley S, Lechner-Scott, Vukcevic D, Christodoulou J.

Value of support: \$872,763.50

Year of funding: 2018-2023

Funding Agency: Jhh Charitable Trust account
Project Title: Further delineation of NK cells in MS activity
Name of Investigators: Jeannette Lechner-Scott, Sean Burnad, Myintzu Min
Value of support: \$ 35, 307
Year of funding: 2017-2018

Funding Agency: NHMRC APP 1127819- NHMRC 2017-2021
Project Title: What predicts the progressive phase of MS?
Name of Investigators: Taylor B, Lucas, R, Lea, R, Kilpatrick T, Scott R, Lechner-Scott J
Value of support: \$1,791,343
Year of funding: 2017-2022

Funding Agency: Biogen Inc
Project Title: Track Australian MS patients
Name of Investigators: Butzkueven H, Kalincik T, Lechner-Scott J, Taylor B, Barnett M
Value of support: \$2,967,594.40
Year of funding: 2017-2022

Funding Agency: MSRA
Project Title: Investigation of erythrocyte microRNA content in Multiple Sclerosis
Name of Investigators: J. Lechner-Scott, Maltby V
Value of support: \$18,000
Year of funding 2017-2018

Funding Agency: Jhh Charitable Trust
Project Title: Can we unveil the Natural Killer cell masquerade behind multiple sclerosis disease activity?
Name of Investigators: J Lechner-Scott, M Min
Value of support: \$20,000
Year of funding: 2017-2018.

Funding Agency: MSRA
Project Title: A Phase II Randomised Controlled Trial of **An** early Tailored **Cognitive Behavioural Therapy Based** Intervention for **Depression** in Those Newly Diagnosed with **Multiple Sclerosis** (ACTION-MS)

Name of Investigators: L. Kiropulos, T. Kilpatrick, Butzkueven H, Lechner-Scott J, Kalincik T,
MacDonald E, Shaw S

Value of support: \$270,044

Year of funding 2016-2018

Funding Agency: Global TEVA

Project Title: Comparison of cognitive screening tools in multiple sclerosis and the association with employment status.

Name of Investigators: Lechner-Scott J, Ribbons K

Value of support: \$67,000

Year 2016

Funding Agency: HMRI

Project Title: Magnetic resonance spectroscopic GABA scanning of brain of MS patients for biochemical changes.

Name of Investigators: Ramadan S, Lechner-Scott J

Value of support: \$20,000

Year 2016

Funding Agency: HMRI

Project Title: The effect of treatment on patients with MS.

Name of Investigators: Maltby V, Lea R, Lechner-Scott J

Value of support: \$20,000

Year 2016

Funding Agency: MSRA

Project Title: Unifying genomics and methylation studies of multiple sclerosis

Name of Investigators: Lechner-Scott J, Maltby V, Lea R, Butzkueven H, Taylor B, Scott R

Value of support: \$220,000

Year 2015-2017

Poster presentation at ectrims in Barcelona 2015, poster presentation at actrims in New Orleans 2016

Publication in Clin Epigenetics in 2015

Funding Agency: Novartis

Project Title: The effect of Gilenya (fingolimod) on cognitive performance in multiple sclerosis

Name of Investigators: Lechner-Scott J, Ribbons K, Mountford C

Value of Support: \$416,061

Year 2014-2018

Poster presentation at ectrims in Barcelona 2016, poster presentation at MSRA meeting in Melbourne 2016

Funding Agency: Biogen

Project Title: Effect of Dimethyl Fumarate (Tecfidera) on microstructure and biochemistry in the brain of MS patients.

Name of Investigators: Lechner-Scott J, Ribbons K, Mountford C

Value of Support: \$ 200,090

Year 2015-2017

Poster presentation at ectrims in Barcelona 2016

Past support

Funding Agency: NHMRC

Project Title: Functional assessment of CD40 in the development of Multiple Sclerosis

Name of investigators: J. Field, H. Butzkueven, D. Booth, T. Kilpatrick, J. Lechner-Scott

Value of Support: \$504,959

Year 2014-2015

Publication in Plos Genetics accepted in 2015

Publication in Plos One in 2014

Funding Agency: HMRI

Project Title: Characterization of non-genetic factors causing Multiple Sclerosis.

Names of Investigators: Maltby V, Lea R, Lechner-Scott J

Value of Support: \$30,000

Year: 2014

Publication in Clin Epigenetics in 2015

Funding Agency: NHMRC

Project title: Clinical implication of IL7R genotype: from disease risk to disease management.

Name of Investigators: G.Stewart, D.Booth, F. McKay, S. Vucic, J. Lechner-Scott et al.

Value of Support: \$606,767

Year 2013-2014

Funding Agency: John Hunter Charitable Trust

Project Title: MicroRNA expression in multiple sclerosis brain tissue

Names of Investigators: Lechner-Scott J, Boyle, M
Value of Support: \$ 12,698.52
Year: 2013
Poster presentation in ectrims/actrims in Boston 2014 and Barcelona in 2015

Funding Agency: CSL
Project title: Prevalence of MS in Newcastle
Name of Investigators: K. Ribbons, J. Lechner-Scott
Value of Support: \$40,000
Year: 2013-2014
Poster presentation at ectrims in Barcelona 2015

Funding Agency: Novartis
Project Title: Gender differences in rate of neuronal degeneration
Name of Investigators: J. Lechner-Scott, K. Ribbons
Value of Support: \$ 67,250
Year: 2012-2013
Poster presentation at ectrims/actrims in Boston 2014

Funding Agency: Bayer Health Care
Project Title: Cytokine in cognition and fatigue in MS, IST
Names of Investigators: J. Lechner-Scott
Value of Support: \$67,000
Year: 2010-2013
Poster presentation at ectrims/actrims in Boston 2014

Funding Agency: Biogen Idec
Project Title: Cytokine in cognition and fatigue in MS, IST
Names of Investigators: J. Lechner-Scott
Value of Support: \$102,000
Year: 2010-2013
Poster presentation at ectrims/actrims in Boston 2014

Funding Agency: John Hunter Hospital Charitable Trust
Project Title: Epigenetic effects on risk of developing Multiple Sclerosis
J. Lechner-Scott, M. Boyle, D. Mossman
Value of Support: \$29,919
Year: 2012

Seeding funding for MSRA grant of \$220,000

Funding Agency: Hunter Medical Research Institute

Project Title: The cytokine gene expression profile in multiple sclerosis patients with chronic fatigue

Names of Investigators: K. Ribbons, J. Lechner-Scott

Value of Support: \$25,000

Year: 2012

Funding Agency: Hunter Medical Research Institute

Project Title: MicroRNA in Multiple Sclerosis

Names of Investigators: J. Lechner-Scott, R. Scott

Value of Support: \$25,000

Year: 2010

Publication in PlosOne in 2010

Funding Agency: Sanofi-Aventis

Project Title: Cytokine in cognition and fatigue in MS, IST

Names of Investigators: J. Lechner-Scott

Value of Support: \$30,000

Year: 2010

Presentation at ectrims in Barcelona in 2015

Funding Agency: NHMRC

Project Title: Susceptibility to Multiple Sclerosis, 633275

Names of Investigators: The ANZGene Consortium

Value of Support: \$836,011

Start Year 2010- End Year 2012.

Publication in Nature Genetics in 2009

Publication in Nature 2011

Funding Agency: Hunter Medical Research Institute

Project Title: Expression profile in Multiple Sclerosis

Names of Investigators: Lechner-Scott J., Scott R.

Value of Support: \$25,000

Year 2011

Publication in Mult Scler 2013

Funding Agency: John Hunter Hospital Charitable Trust

Project Title: Association of intrathecal antibody production with P2X7 gene polymorphism
Names of Investigators: Lechner-Scott J., Williams D.
Value of Support: \$18,000
Year: 2011
Publication in Hum Mol Gen in 2015

Funding Agency: Hunter Medical Research Institute
Project Title: The cytokine gene expression profile in multiple sclerosis patients with chronic fatigue
Names of Investigators: Ribbons K., Lechner-Scott J.
Value of Support: \$25,000
Year: 2011
Presentation at ectrims in Barcelona in 2015

Funding Agency: John Hunter Hospital Charitable Trust
Project Title: Expression profile in Multiple Sclerosis
Names of Investigators: Lechner-Scott J, Boyle M.
Value of Support: \$29,000
Year: 2011
Publication in Mult Scler in 2013

Funding Agency: Sanofi-Aventis
Project Title: Cytokine in cognition and fatigue in MS, IST
Names of Investigators: Lechner-Scott J.
Value of Support: \$30,000
Year: 2010
Presentation at ectrims in Barcelona in 2015

Funding Agency: NHMRC
Project Title: Finemapping of Chromosome 12, 628705
Names of Investigators: The Australia and New Zealand Multiple Sclerosis Genetics Consortium
Value of Support: \$820,000
Start Year: 2009 - End Year: 2009
Publication in Nature Genetics in 2009
Publication in Nature 2011

Funding Agency: Brain Foundation
Project Title: ANZ NMO Collaboration
Names of Investigators: S. Broadley, R. Heard, B. Brew, J. Lechner-Scott
Value of Support: \$40,000
Start Year: 2009 – End Year: 2009
Presentation at Pactrims 2015 in Seoul

Funding Agency: John Hunter Hospital Charitable Trust

Project Title: Disease specific polymorphisms in MS

Names of Investigators: J. Lechner-Scott, D. Williams

Value of Support: \$15,208

Start Year: 2008 - End Year: 2008

Publication in Mult Scler 2012

Funding Agency: MSRA

Project Title: Immunogenetic Profiles in MS

Names of Investigators: J. Lechner-Scott, R.J. Scott, D. Williams, P. Mascato

Value of Support: \$40,000

Start Year: 2006 - End Year: 2007

Publication in Nature Genetics in 2009

Publication in Nature 2011

Funding Agency: Australian Research Council (ARC)

Project Title: Identifying genes for clinical course and susceptibility in multiple sclerosis

Names of Investigators: Kilpatrick T., Perreau V., Foote S.J., Griffiths L.R., Stankovich J.M., Rubio J.P., Bahlo M., Booth D.R., Butzkueven H., Heard R., Lechner-Scott J., Wiley J.S.

Value of Support: \$400,000

Start Year: 2007 - End Year: 2009

Publication in Nature Genetics in 2009

Publication in Nature 2011

Funding Agency: Newcastle Permanent Building Society

Project Title: GeMeSiS - Immunogenetic Profiles in MS

Names of Investigators: J. Lechner-Scott

Value of Support: \$17,850

Start Year: 2007 - End Year: 2007

Publication in Nature Genetics in 2009

Publication in Nature 2011

Funding Agency: John Hunter Hospital Charitable Trust

Project Title: Immunogenetic Profiles in MS

Names of Investigators: J. Lechner-Scott, R.J. Scott, D. Williams, P. Moscato

Value of Support: \$12,850

Start Year: 2005 – End Year: 2005

Publication in Nature Genetics in 2009

Publication in Nature 2011

Peer Reviewed Articles

6237 citations

h-Index 32

i10 index 76

Period 1990-2000

1 Carstens, E., Leah, J., **Lechner, J.** and Zimmermann, M. (1990) Demonstration of extensive brainstem projections to medial and lateral thalamus and hypothalamus in the rat. *Neuroscience* 35: 609-626. IF=3.5 CI= 63

2 **Lechner, J.**, Leah, J. and Zimmermann, M. (1993) Brainstem peptidergic neurons projecting to the medial and lateral thalamus, and zona incerta in the rat. *Brain Res.* 603: 47-56. IF= 2.5 CI=30

3 **Lechner, J.**, Steiger, R. and Ochsner, P. (1993) Die operative Behandlung der Galeazzi-Fraktur. *Unfallchir.* 96: 18-23. IF=0.6 CI=3

4 **Lechner-Scott, J.**, Scott, R. Steck, A.J. und Kappos, L. (1995) Hereditäre motorisch-sensible Neuropathien. Klinische und molekulargenetische Aspekte. *Schweizer Archiv Neurol.* 146: 157-167.

*5 **Lechner-Scott, J.**, Engelter, S., Steck, A.J., Dellas, S., Tolnay, M., Probst, A. (1996) A case of cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy confirmed by sural nerve biopsy. *J.Neurol. Neurosurg. Psych.* 60: 235-236. IF=4.8 Citations 16

6 Huber, S., Spycher, M., **Lechner-Scott, J.**, Bellaiche, Y., Steck, A.J., Kappos, L. (1996) Multiple Sklerose: Therapie mit rekombinanten Interferon beta 1b. *Schweiz. Med. Wochenschr.* 126: 1475-1481.

*7 Roelcke, U., Kappos, L. **Lechner-Scott J** et al. (1997) Reduced glucose metabolism in the caudate nucleus and prefrontal cortex in multiple sclerosis patients with fatigue. A ¹⁸F-fluorodeoxyglucose positron emission tomography study. *Neurology* 48: 1566-1571. IF= 4.6 . Citations 221

*8 Willimann, P., **Lechner-Scott, J.**, Ferracin, F., Miescher, G., Steck, A.J. (1997) klinische Bedeutung der Anti-GQ1b-Antikörper bei Patienten mit Miller-Fisher-Syndrom. Akt. Neurologie 24: 67-70.

9 **Lechner-Scott, J.**, Steck, A.J., Scott R. J. (1997) Genetische Untersuchungen in der Neurologie. Schweiz. Med. Wochenschr. 127: 1141-1153.

10 G. Scollo-Lavizzari und **J. Lechner-Scott** (1997) Synkopen aus neurologischer Sicht. Therapeut. Umschau 54: 135-143.

*11 Plohm, A., M., Kappos, L., Ammann, W., Thordai, A., Wittwer, A., Bellaiche, Y., Huber, S., **Lechner-Scott, J.** (1998) Computer assisted retraining of attentional impairments in patients with Multiple Sclerosis. J. Neurol. Neurosurg. Psychiatry 64: 455-462.

12 Confavreux, C., Hutchinson, M., Hours, M.F., Cortinovis, P., Moreau, T. et al. (1998) Rate of pregnancy-related relapse in multiple sclerosis. N Engl. J. Med. 339: 285-291. IF=22.4 CI= 640

13 European Study Group (1998) Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 352: 1491-1497. IF=30.7 CI=580

14 Lienert C, **Lechner-Scott J**, Schött D, Constantinescu C, Kappos L (1999) Use of composite scores in the quantification of deterioration in multiple sclerosis. Multiple Sclerosis 5: 220-222.

15 Ritz MF, **Lechner-Scott J**, Scott RJ, Steck AJ (2000) Autoantibodies to PMP22 in patients with hereditary and acquired neuropathies. J. of Neuroimmunology 104: 155-163.

Period 2000-2010

*16 **Lechner-Scott J**, Kappos L, Hofman M, Polman Ch, Montalban X., Frontoni M et al. (2003) Can the Expanded Disability Status Scale (EDSS) be assessed by phone? Multiple Sclerosis 9: 154-159.

17 Vukusic S, Hutchinson M, Hours M, Moreau T, Cortinovis-Tourniaire P, Adeleine P, Confavreux C, The Pregnancy In Multiple Sclerosis Group; Pregnancy In MultipleSclerosis Group. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain. 2004 Jun;127(Pt 6):1353-60. Epub 2004 May 6.

18 Stankovich J, Butzkueven H, Marriott M, Chapman C, Tubridy N, Taite BD, Varney D, Taylor B, Foote SH, The **ANZGene** Consortium, Kilpatrick TJ, Rubio JP. HLA-DRB1 associations with disease susceptibility and clinical course in Australians with multiple sclerosis. Tissue Antigens. 2009 Jul;74(1):17-21. Epub 2009 Apr 21.

*19The Australia and New Zealand Multiple Sclerosis Genetics Consortium (**ANZgene**)*Genome-wide association scan identifies novel multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat Genet. 2009 Jul;41(7):824-8. Epub 2009 Jun 14.

20 Bahlo M, Stankovich J, Danoy P, Hickey PF, Taylor BV, Browning SR, The **Australian and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene)***, Brown MA, Rubio JP. Saliva derived DNA performs well in large-scale, high-density SNP microarray studies. Cancer Epidemiol Biomarkers Prev. 2010 Mar;19(3):794-8. IF=4.3

21 Jensen CJ, Stankovich J, Van der Walt A, Bahlo M, Taylor BV, van der Mei IA, Foote SJ, Kilpatrick TJ, Johnson LJ, Wilkins E, Field J, Danoy P, Brown MA; **Australian and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene)**, Rubio JP, Butzkueven H. Multiple sclerosis susceptibility-associated SNPs do not influence disease severity measures in a cohort of Australian MS patients. PLoS One. 2010 Apr 2;5(4):e10003. IF=4.35

*22 Gandhi KS, McKay FC, Cox MB, Riveros C, Heard RN, Vucic S, Williams DW, Stankovich J, Brown M, Danoy P, Stewart GJ, Broadley S, Moscato P, **Lechner-Scott J**, Scott RJ, Booth DR, ANZgene Multiple Sclerosis Genetics Consortium. The multiple sclerosis whole blood mRNA transcriptome and genetic associations indicate dysregulation of specific T cell pathways in pathogenesis. Hum Mol Gen 2010 Jun 1;19(11):2134-43. IF=7.38 CI=9

23 Ban M, McCauley JL, Zuvich R, Baker A, Bergamaschi L, Cox MB, Kempainen A, D'Alfonso S, **Lechner-Scott J**, DeJager P, Hafler DA, Barcellos LF, Ivanson AJ, Percak-Vance MA, Oksenberg JR, Hauser SL, Sexton D, Haines J, Compston A, Sawcer S. A non-synonymous SNP within membrane metalloproteinase-like 1 (MMEL1) is associated with multiple sclerosis. *Genes Immun* 2010; Jun 24. IF=4.2

24 International Multiple Sclerosis Genetics Consortium (IMSGC)* Booth D, Heard R, Stewart G, Cox MB, Scott RJ, **Lechner-Scott J** et al. Lack of support for association between the KIF1B rs10492972[C] variant and multiple sclerosis. *Nat Genet.* 2010 Jun;42(6):469-70. IF=26.446

25 **Lechner-Scott J**, Kerr T, Spencer B, Agland S, Lydon A, Schofield PW. The Audio recorded Cognitive Screen (ARCS) in patients with Multiple Sclerosis: A practical tool for MS clinics. *Mult Scler.* 2010 Sep;16(9):1126-33.

26 International Multiple Sclerosis Genetics Consortium (IMSGC). [IL12A](#), MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci. *Genes Immun.* 2010 Jul;11(5):397-405. Epub 2010 Jun 17.

*27 Cox MB, Cairns MJ, Gandhi KS, Carroll AP, Moscovis S, Stewart G, Broadley S, Scott RJ, Booth DR, **Lechner-Scott J**, ANZgene Consortium. MicroRNAs miR-17 and miR-20a inhibit T cell activation genes and are under-expressed in MS whole blood. *PLoS One.* 2010 Aug 11;5(8):e12132.

28 Field, J, Browning SR, Johnson LJ, Danoy P, Varney MD, Tait BD, Gandhi KS, Charlesworth JC, Heard RN, **ANZGene Consortium**, Stewart GJ, Kilpatrick TJ, Foote, SJ, Bahlo M, Butzkueven H, Wiley JW, Booth DR, Taylor BV, Brown MA, Rubio JP, Stankovich J. A polymorphism in the HLA-DPB1 gene is associated with susceptibility to multiple sclerosis. *PLoS One.* 2010 Oct 26;5(10):e13454. IF=4.3

29 Riveros C, Mellor D, Gandhi KS, McKay FC, Cox MB, Berretta R, Vaezpour SY, Inostroza-Ponta M, Broadley SA, Heard RN, Vucic S, Stewart GJ, Williams DW, Scott RJ, **Lechner-Scott J**, Booth DR, Moscato P; ANZgene Multiple Sclerosis Genetics Consortium. A transcription factor map as revealed by a genome-wide gene expression analysis of whole-blood mRNA transcriptome in multiple sclerosis *PLoSOne.* 2010 Dec 1;5(12):e14176

Period from 2011

30 Ritchie ME, Carvalho BS, Hetrick KN, Irizarry RA and The Australian and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene Consortium) Comparing genotyping algorithms for Illumina's Infinum whole-genome SNP BeadChips. *BMC Bioinformatics*. 2011 Mar 8;12:68 IF=4.9

31 Ma GZ, Stankovich J; Australia and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene), Kilpatrick TJ, Binder MD, Field J. Polymorphisms in the Receptor Tyrosine Kinase MERTK Gene Are Associated with Multiple Sclerosis Susceptibility. *PlosOne* 2011 Feb 8(6),e16964. IF=4.3

32 Wang J, Pappas D, De Jager P, Pelletier J, deBakker PW, Kappos L, Polman CH, Australian and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene), Chibnik LB, Hafler DF, Matthews PM, Hauser SL, Baranzini SE, Oksenberg JR Modeling the Cumulative Genetic Risk for Multiple Sclerosis from Genome Wide Association Data. *Genome Med*. 2011 Jan 18;3(1):3. IF=2.6

33 O'Gorman C, Freeman S, Taylor BV, Butzkueven H Australian and New Zealand MS Genetics Consortium (ANZgene), Broadley SA. Familial recurrence risks for multiple sclerosis in Australia. *J Neurol Neurosurg Psychiatry*. 2011 Dec;82(12):1351-4. IF=4.8.

34 The International Multiple Sclerosis Genetics Consortium (IMSGC) and the Wellcome Trust Case Control Consortium 2 (WTCCC2)*. International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2, Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L, Dilthey A, Su Z, Freeman C, Hunt SE, Edkins S, Gray E, Booth DR, Potter SC, Goris A, Band G, Oturai AB, Strange A, Saarela J, Bellenguez C, Fontaine B, Gillman M, Hemmer B, Gwilliam R, Zipp F, Jayakumar A, Martin R, Leslie S, Hawkins S, Giannoulatou E, D'alfonso S, Blackburn H, Martinelli Boneschi F, Liddle J, Harbo HF, Perez ML, Spurkland A, Waller MJ, Mycko MP, Ricketts M, Comabella M, Hammond N, Kockum I, McCann OT, Ban M, Whittaker P, Kempainen A, Weston P, Hawkins C, Widaa S, Zajicek J, Dronov S, Robertson N, Bumpstead SJ, Barcellos LF, Ravindrarajah R, Abraham R, Alfredsson L, Ardlie K, Aubin C, Baker A, Baker K, Baranzini SE, Bergamaschi L, Bergamaschi R,

Bernstein A, Berthele A, Boggild M, Bradfield JP, Brassat D, Broadley SA, Buck D, Butzkueven H, Capra R, Carroll WM, Cavalla P, Celius EG, Cepok S, Chiavacci R, Clerget-Darpoux F, Clysters K, Comi G, Cossburn M, Cournu-Rebeix I, Cox MB, Cozen W, Cree BA, Cross AH, Cusi D, Daly MJ, Davis E, de Bakker PI, Debouverie M, D'hooghe MB, Dixon K, Dobosi R, Dubois B, Ellinghaus D, Elovaara I, Esposito F, Fontenille C, Foote S, Franke A, Galimberti D, Ghezzi A, Glessner J, Gomez R, Gout O, Graham C, Grant SF, Guerini FR, Hakonarson H, Hall P, Hamsten A, Hartung HP, Heard RN, Heath S, Hobart J, Hoshi M, Infante-Duarte C, Ingram G, Ingram W, Islam T, Jagodic M, Kabesch M, Kermode AG, Kilpatrick TJ, Kim C, Klopp N, Koivisto K, Larsson M, Lathrop M, **Lechner-Scott JS**, Leone MA, Leppä V, Liljedahl U, Bomfim IL, Lincoln RR, Link J, Liu J, Lorentzen AR, Lupoli S, Macciardi F, Mack T, Marriott M, Martinelli V, Mason D, McCauley JL, Mentch F, Mero IL, Mihalova T, Montalban X, Mottershead J, Myhr KM, Naldi P, Ollier W, Page A, Palotie A, Pelletier J, Piccio L, Pickersgill T, Piehl F, Pobywajlo S, Quach HL, Ramsay PP, Reunanen M, Reynolds R, Rioux JD, Rodegher M, Roesner S, Rubio JP, Rückert IM, Salvetti M, Salvi E, Santaniello A, Schaefer CA, Schreiber S, Schulze C, Scott RJ, Sellebjerg F, Selmaj KW, Sexton D, Shen L, Simms-Acuna B, Skidmore S, Sleiman PM, Smestad C, Sørensen PS, Søndergaard HB, Stankovich J, Strange RC, Sulonen AM, Sundqvist E, Syvänen AC, Taddeo F, Taylor B, Blackwell JM, Tienari P, Bramon E, Tourbah A, Brown MA, Tronczynska E, Casas JP, Tubridy N, Corvin A, Vickery J, Jankowski J, Villoslada P, Markus HS, Wang K, Mathew CG, Wason J, Palmer CN, Wichmann HE, Plomin R, Willoughby E, Rautanen A, Winkelmann J, Wittig M, Trembath RC, Yaouanq J, Viswanathan AC, Zhang H, Wood NW, Zuvich R, Deloukas P, Langford C, Duncanson A, Oksenberg JR, Pericak-Vance MA, Haines JL, Olsson T, Hillert J, Ivinson AJ, De Jager PL, Peltonen L, Stewart GJ, Hafler DA, Hauser SL, McVean G, Donnelly P, Compston A Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. *Nature*. 2011 Aug 10;476(7359):214-9 IF=34.5

35 Malhotra S, Morcillo-Suárez C, Brassat D, Goertsches R, **Lechner-Scott J**, Urcelay E, Fernández O, Drulovic J, García-Merino A, Martinelli Boneschi F, Chan A, Vandenbroeck K, Navarro A, Bustamante MF, Río J, Akkad DA, Giacalone G, Sánchez AJ, Leyva L, Alvarez-Lafuente R, Zettl UK, Oksenberg J, Montalban X, Comabella M IL28B polymorphisms are not associated with the response to interferon-beta in multiple sclerosis. *J Neuroimmunol*. 2011 Oct 28;239(1-2):101-4.

36 Cox MB, Ban M, Bowden N, Baker A, Scott RJ, **Lechner-Scott J**. Potential association of Vitamin D polymorphism TaqI with multiple sclerosis. *Mult Scler*. 2012 Jan;18(1):16-22

*37 **Lechner-Scott J**, Spencer B, de Malmanche T, Attia J, Fitzgerald M, Trojano M, Grand'maison F, Antonio C Gomez J, Izquierdo G, Duquette P, Girard M, Grammond P, Oreja-Guevara C, Hupperts R, Bergamaschi R, Boz C, Giuliani G, Pesch VV, Iuliano G, Fiol M, Cristiano E, Verheul F, Saladino ML, Slee M, Barnett M, Deri N, Fletcher S, Vella N, Shaw C, Herbert J, Moore F, Petkovska-Boskova T, Jokubatis V, Butzkueven H. The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. *Mult Scler*. 2012 Jul;18(7):974-82.

38 Patsopoulos NA; Bayer Pharma MS Genetics Working Group; Steering Committees of Studies Evaluating IFN β -1b and a CCR1-Antagonist; ANZgene Consortium; GeneMSA; International Multiple Sclerosis Genetics Consortium, Esposito F, Reischl J, Lehr S, Bauer D, Heubach J, Sandbrink R, Pohl C, Edan G, Kappos L, Miller D, Montalbán J, Polman CH, Freedman MS, Hartung HP, Arnason BG, Comi G, Cook S, Filippi M, Goodin DS, Jeffery D, O'Connor P, Ebers GC, Langdon D, Reder AT, Traboulsee A, Zipp F, Schimrigk S, Hillert J, Bahlo M, Booth DR, Broadley S, Brown MA, Browning BL, Browning SR, Butzkueven H, Carroll WM, Chapman C, Foote SJ, Griffiths L, Kermode AG, Kilpatrick TJ, **Lechner-Scott J**, Marriott M, Mason D, Moscato P, Heard RN, Pender MP, Perreau VM, Perera D, Rubio JP, Scott RJ, Slee M, Stankovich J, Stewart GJ, Taylor BV, Tubridy N, Willoughby E, Wiley J, Matthews P, Boneschi FM, Compston A, Haines J, Hauser SL, McCauley J, Ivinson A, Oksenberg JR, Pericak-Vance M, Sawcer SJ, De Jager PL, Hafler DA, de Bakker PI. Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. *Ann Neurol*. 2011 Dec;70(6):897-912. Citations 57

39 Hughes S, Spelman T, Trojano M, Lugaresi A, Izquierdo G, Grand'Maison F, Duquette P, Girard M, Grammond P, Oreja-Guevara C, Hupperts R, Boz C, Bergamaschi R, Giuliani G, Rio ME, **Lechner-Scott J**, Butzkueven H on behalf of the MSBase Study Group. The Kurtzke EDSS rank stability increases 4 years after onset of Multiple Sclerosis: results from the MSBase Registry. *J Neurol Neurosurg Psychiatry*. 2012 Mar;83(3):305-10.

40 Kister I, Chamot E, Cutter G, Bacon TE, Jokubaitis VG, Hughes SE, Gray OM, Trojano M, Izquierdo G, Grand'maison F, Duquette P, Lugaresi A, Grammond P, Boz C, Hupperts R, Petersen T, Giuliani G, Oreja-Guevara C, Iuliano G, **Lechner-Scott J**, Bergamaschi R, Rio ME, Verheul F, Fiol M, Van Pesch V, Slee M, Butzkueven H, Herbert J; with the MSBase Investigators. Increasing age at disability milestones among MS patients in the MSBase Registry. *J Neurol Sci.* 2012 Jul 15;318(1-2):94-9.

41 Meyniel C, Spelman T, Buzzard K, Jokubaitis VG, Rutherford M, Trojano M, Zwanikken C, Lugaresi A, Izquierdo G, Duquette P, Girard M, Grand'Maison F, Grammond P, Oreja-Guevara C, Hupperts R, Boz C, Petersen T, Bergamaschi R, Giuliani G, **Lechner-Scott J**, Barnett M, Rio ME, Van Pesch V, Iuliano G, Fiol M, Verheul F, Slee M, Cristiano E, Shaygannejad V, Fernandez-Bolanos R, Poehlau D, Saladino ML, Oleschko Arruda W, Deri N, Flechter S, Paine M, Herbert J, Cabrera-Gomez JA, Skromne E, Vella N, Savino A, Shaw C, Moore F, Bacile E, Vucic S, Petkovska-Boskova T, Santiago V, Jolley D, Butzkueven H. Country, Sex EDSS change and therapy choice predict treatment discontinuation in CIS and MS. *PLoS One.* 2012;7(6):e38661. Epub 2012 Jun 29

42 Yan J, Liu J, Yihao Lin C, Australia and New Zealand Multiple Sclerosis Genetics Consortium (ANZGene), Csurhes PA, Pender MP, McCombe PA, Greer JA The -572 promoter region C allele in the interleukin-6 gene may play a role in rate of disease progression in multiple sclerosis. *Int J Mol Sci.* 2012 Oct 22;13(10):13667-79.

43 Trojano M, Lucchese G, Graziano G, Taylor BV, Simpson S Jr, Lepore V, Grand'maison F, Duquette P, Izquierdo G, Grammond P, Amato MP, Bergamaschi R, Giuliani G, Boz C, Hupperts R, Van Pesch V, **Lechner-Scott J**, Cristiano E, Fiol M, Oreja-Guevara C, Saladino ML, Verheul F, Slee M, Paolicelli D, Tortorella C, D'Onghia M, Iaffaldano P, Direnzo V, Butzkueven H; MSBase Study Group and the New Zealand MS Prevalence Study Group. Geographical Variations in Sex Ratio Trends over Time in Multiple Sclerosis. *PLoS One.* 2012;7(10):e48078. doi: 10.1371/journal.pone.0048078. Epub 2012 Oct 25

★44 Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, Dawson KT; DEFINE Study Investigators. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. *N Engl J Med.* 2012 Sep 20;367(12):1098-107

45 Verheul F, Smolders J, Trojano M, Lepore V, Zwanikken C, Amato MP, Grand'maison F, Butzkueven H, Marrosu M, Duquette P, Comi G, Izquierdo G,

Grammond P, Lus G, Petersen T, Bergamaschi R, Giuliani G, Boz C, Coniglio G, Van Pesch V, **Lechner-Scott J**, Cavalla P, Granella F, Avolio C, Fiol M, Poehlau D, Saladino ML, Gallo P, Deri N, Oleschko Arruda W, Paine M, Ferro M, Barnett M, Cabrera-Gomez JA, Slee M, Moore F, Shaw C, Petkovska-Boskova T, Rutherford M, Engelsen O, Damoiseaux J, Hupperts R. Fluctuations of MS births and UV-light exposure. *Acta Neurol Scand.* 2013 May;127(5):301-8.

46 Lill CM, Liu T, Schjeide BM, Roehr JT, Akkad DA, Damotte V, Alcina A, Ortiz MA, Arroyo R, Lopez de Lapuente A, Blaschke P, Winkelmann A, Gerdes LA, Luessi F, Fernadez O, Izquierdo G, Antigüedad A, Hoffjan S, Cournu-Rebeix I, Gromöller S, Faber H, Liebsch M, Meissner E, Chanvillard C, Touze E, Pico F, Corcia P; **ANZgene Consortium**, Dörner T, Steinhagen-Thiessen E, Baeckman L, Heekeren HR, Li SC, Lindenberger U, Chan A, Hartung HP, Aktas O, Lohse P, Kümpfel T, Kubisch C, Epplen JT, Zettl UK, Fontaine B, Vandenbroeck K, Matesanz F, Urcelay E, Bertram L, Zipp F. Closing the case of APOE in multiple sclerosis: no association with disease risk in over 29 000 subjects. *J Med Genet.* 2012 Sep;49(9):558-62. doi: 10.1136/jmedgenet-2012-101175

47 Lee SH, Harold D, Nyholt DR, **ANZGene Consortium**, ENDOGENE Consortium, the Genetic and Environmental Risk for Alzheimer's disease (GERAD1) Consortium, Goddard ME, Zondervan KT, Williams J, Montgomery GW, Wray NR, Visscher PM Estimation and partitioning of polygenic variation captured by common SNPs. for Alzheimer's disease, multiple sclerosis and endometriosis. *Hum Mol Genet.* 2013 Feb 15;22(4):832-841.

48 Cox MB, Bowden NA, Scott RJ, **Lechner-Scott J** Altered expression of the plasminogen activation pathway in peripheral blood mononuclear cells in multiple sclerosis: possible pathomechanism of matrix metalloproteinase activation. *Mult Scler.* 2013 Sep;19(10):1268-74.

49 Cortes A, Field J, Glazov EA, Hadler J; **ANZGene Consortium**, Stankovich J, Brown MA. Resequencing and fine-mapping of the chromosome 12q13-14 locus associated with multiple sclerosis refines the number of implicated genes. *Hum Mol Genet.* 2013 Jun 1;22(11):2283-92.

50 Jokubatis V, Liew D, Spelman T, Barnett M, Lechner-Scott J, Slee M, Vucic S, Butzkueven H The Australian Multiple Sclerosis (MS) Immunotherapy Study: A

prospective, multicentre study of drug utilisation using the MSBase platform. PLoS One. 2013;8(3):e59694.

51 Lin R, Charlesworth J, Stankovich J, Perreau VM, Brown MA, ANZgene Consortium, Taylor BV Identity-by-Descent Mapping to Detect Rare Variants Conferring Susceptibility to Multiple Sclerosis. PloS one March 2013 8(3) e56379.

52 Kalincik T, Spelman T, Trojano M, Duquette P, Izquierdo G, Grammond P, Lugaresi A, Hupperts R, Cristiano E, Van Pesch V, Grand'maison F, La Spitaleri D, Rio ME, Flechter S, Oreja-Guevara C, Giuliani G, Savino A, Amato MP, Petersen T, Fernandez-Bolanos R, Bergamaschi R, Iuliano G, Boz C, **Lechner-Scott** J, Deri N, Gray O, Verheul F, Fiol M, Barnett M, van Munster E, Santiago V, Moore F, Slee M, Saladino ML, Alroughani R, Shaw C, Kasa K, Petkovska-Boskova T, den Braber-Moerland L, Chapman J, Skromne E, Herbert J, Poehlau D, Needham M, Bacile EA, Arruda WO, Paine M, Singhal B, Vucic S, Cabrera-Gomez JA, Butzkueven H; MSBase Study Group¶, Roger E, Despault P, Marriott M, Van der Walt A, King J, Kilpatrick T, Buzzard K, Jokubaitis V, Byron J, Morgan L, Skibina O, Haartsen J, De Luca G, Di Tommaso V, Travaglini D, Pietrolongo E, di Ioia M, Farina D, Mancinelli L, Paolicelli D, Iaffaldano P, Ignacio Rojas J, Patrucco L, Roullet E, Correale J, Ysraelit C, Elisabetta C, Pucci E, Williams D, Dark L, Shaygannejad V, Zwanikken C, Vella N, Sirbu CA. Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon Beta 1a dosages for multiple sclerosis. PLoS One. 2013 May 21;8(5):e63480. doi: 10.1371/journal.pone.0063480.

53 Mechelli R, Umeton R, Policano C, Annibali V, Coarelli G, Ricigliano VA, Vittori D, Fornasiero A, Buscarinu MC; International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium,2, Romano S, Salvetti M, Ristori G. "A candidate-interactome" aggregate analysis of genome-wide association data in multiple sclerosis. PLoS One. 2013 May 16;8(5):e63300

54 Cox MB, Bowden NA, Scott RJ, **Lechner-Scott** J. Common genetic variants in the plasminogen activation pathway are not associated with multiple sclerosis. Mult Scler. 2014 Apr;20(4):489-91

55 Hughes S, Spelman T, Gray OM, Trojano M, Duquette P, Izquierdo G, Grammond P, Lugaresi A, Hupperts R, Cristiano E, Van Pesch V, Grand'maison F, La Spitaleri D, Rio

ME, Flechter S, Oreja-Guevara C, Giuliani G, Savino A, Amato MP, Petersen T, Fernandez-Bolanos R, Bergamaschi R, Iuliano G, Boz C, **Lechner-Scott J**, Deri N, Gray O, Verheul F, Fiol M, Barnett M, van Munster E, Santiago V, Moore F, Slee M, Saladino ML, Alroughani R, Shaw C, Kasa K, Petkovska-Boskova T, den Braber-Moerland L, Chapman J, Skromne E, Herbert J, Poehlau D, Needham M, Bacile EA, Arruda WO, Paine M, Singhal B, Vucic S, Cabrera-Gomez JA, Butzkueven H; MSBase Study Group¶, Roger E, Despault P, Marriott M, Van der Walt A, King J, Kilpatrick T, Buzzard K, Jokubaitis V, Byron J, Morgan L, Skibina O, Haartsen J, De Luca G, Di Tommaso V, Travaglini D, Pietrolongo E, di Ioia M, Farina D, Mancinelli L, Paolicelli D, Iaffaldano P, Ignacio Rojas J, Patrucco L, Roullet E, Correale J, Ysrraelit C, Elisabetta C, Pucci E, Williams D, Dark L, Shaygannejad V, Zwanikken C, Vella N, Sirbu CA. Predictors and dynamics of postpartum relapses in women with multiple sclerosis. *Mult Scler.* 2013 Oct 9

★¶56 Kalincik T, Vivek V, Jokubaitis V, **Lechner-Scott J**, Trojano M, Izquierdo G, Lugaresi A, Grand'maison F, Hupperts R, Oreja-Guevara C, Bergamaschi R, Iuliano G, Alroughani R, Van Pesch V, Amato MP, Slee M, Verheul F, Fernandez-Bolanos R, Fiol M, Spitaleri DL, Cristiano E, Gray O, Cabrera-Gomez JA, Shaygannejad V, Herbert J, Vucic S, Needham M, Petkovska-Boskova T, Sirbu CA, Duquette P, Girard M, Grammond P, Boz C, Giuliani G, Rio ME, Barnett M, Flechter S, Moore F, Singhal B, Bacile EA, Saladino ML, Shaw C, Skromne E, Poehlau D, Vella N, Spelman T, Liew D, Kilpatrick TJ, Butzkueven H; on behalf of the MSBase Study Group. Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. *Brain.* 2013 Oct 18. [Epub ahead of print]

57 Graves MC, Benton M, Lea RA, Boyle M, Tajouri L, Macartney-Coxson D, Scott RJ and **Lechner-Scott J**. Methylation differences at the HLA-DRB1 locus in CD4+ T-Cells are associated with multiple sclerosis. *Mult Scler.* 2013 Dec 12;20(8):1033-1041.

★¶58 International Multiple Sclerosis Genetics Consortium (IMSGC), Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kempainen A, Cotsapas C, Shah TS, Spencer C, Booth D, Goris A, Oturai A, Saarela J, Fontaine B, Hemmer B, Martin C, Zipp F, D'Alfonso S, Martinelli-Boneschi F, Taylor B, Harbo HF, Kockum I, Hillert J, Olsson T, Ban M, Oksenberg JR, Hintzen R, Barcellos LF; Wellcome Trust Case Control Consortium 2 (WTCCC2); International IBD Genetics Consortium (IIBDGC), Agliardi C, Alfredsson L, Alizadeh M, Anderson C, Andrews R, Søndergaard HB, Baker A, Band G, Baranzini SE, Barizzone N, Barrett J, Bellenguez C, Bergamaschi L, Bernardinelli L, Berthele A, Biberacher V, Binder TM, Blackburn H, Bomfim IL, Brambilla P, Broadley S,

Brochet B, Brundin L, Buck D, Butzkueven H, Caillier SJ, Camu W, Carpentier W, Cavalla P, Celius EG, Coman I, Comi G, Corrado L, Cosemans L, Courno-Rebeix I, Cree BA, Cusi D, Damotte V, Defer G, Delgado SR, Deloukas P, di Sapio A, Diltthey AT, Donnelly P, Dubois B, Duddy M, Edkins S, Elovaara I, Esposito F, Evangelou N, Fiddes B, Field J, Franke A, Freeman C, Frohlich IY, Galimberti D, Gieger C, Gourraud PA, Graetz C, Graham A, Grummel V, Guaschino C, Hadjixenofontos A, Hakonarson H, Halfpenny C, Hall G, Hall P, Hamsten A, Harley J, Harrower T, Hawkins C, Hellenthal G, Hillier C, Hobart J, Hoshi M, Hunt SE, Jagodic M, Jelčić I, Jochim A, Kendall B, Kermodé A, Kilpatrick T, Koivisto K, Konidari I, Korn T, Kronsbein H, Langford C, Larsson M, Lathrop M, Lebrun-Frenay C, **Lechner-Scott** J, Lee MH, Leone MA, Leppä V, Liberatore G, Lie BA, Lill CM, Lindén M, Link J, Luessi F, Lycke J, Macciardi F, Männistö S, Manrique CP, Martin R, Martinelli V, Mason D, Mazibrada G, McCabe C, Mero IL, Mescheriakova J, Moutsianas L, Myhr KM, Nagels G, Nicholas R, Nilsson P, Piehl F, Pirinen M, Price SE, Quach H, Reunanen M, Robberecht W, Robertson NP, Rodegher M, Rog D, Salvetti M, Schnetz-Boutaud NC, Sellebjerg F, Selter RC, Schaefer C, Shaunak S, Shen L, Shields S, Siffrin V, Slee M, Sorensen PS, Sorosina M, Sospedra M, Spurkland A, Strange A, Sundqvist E, Thijs V, Thorpe J, Ticca A, Tienari P, van Duijn C, Visser EM, Vucic S, Westerlind H, Wiley JS, Wilkins A, Wilson JF, Winkelmann J, Zajicek J, Zindler E, Haines JL, Pericak-Vance MA, Ivinson AJ, Stewart G, Hafler D, Hauser SL, Compston A, McVean G, De Jager P, Sawcer SJ, McCauley JL. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. *Nat Genet.* 2013 Nov;45(11):1353-60. Citations 420. IF 35.2

59 Parnell GP, Gatt PN, McKay FC, Schibeci S, Krupa M, Powell JE, Visscher PM, Montgomery GW, **Lechner-Scott** J, Broadley S, Liddle C, Slee M, Vucic S, Stewart GJ, Booth DR. Ribosomal protein S6 mRNA is a biomarker upregulated in multiple sclerosis, downregulated by interferon treatment, and affected by season. *Mult Scler.* 2014 May;20(6):675-85. IF 4.47

60 Shahjani F, Parnell GP, McKay FC, Gatt PN, Shojoei M, O'Connor KS, Schibeci SD, Brilot F, Liddle C, Batten M; **ANZgene** Multiple Sclerosis Genetics Consortium, Stewart GJ, Booth DR. The CYP27B1 variant associated with increased risk of autoimmune disease is underexpressed in tolerising dendritic cells. *Hum Mol Genet.* 2014 Mar 15;23(6):1425-34. IF 7.7

61 Patsopoulos NA, Barcellos LF, Hintzen RQ, Schaefer C, van Duijn CM, Noble JA, Raj T; IMSGC; ANZgene, Gourraud PA, Stranger BE, Oksenberg J, Olsson T, Taylor BV, Sawcer S, Hafler DA, Carrington M, De Jager PL, de Bakker PI. Fine-Mapping the

Genetic Association of the Major Histocompatibility Complex in Multiple Sclerosis: HLA and Non-HLA Effects. *PLoS Genet.* 2013 Nov;9(11):e1003926. doi: 10.1371/journal.pgen.1003926. Epub 2013 Nov 21 IF 8.5

62 Jokubaitis VG, Li V, Kalincik T, Li V, Izquierdo G, Hodgkinson S, Alroughani R, Lechner-Scott J, Lugaresi A, Duquette P, Girard M, Barnett M, Grand'Maison F, Trojano M, Slee M, Giuliani G, Shaw C, Boz C, Spitaleri D, Verheul F, Haartsen J, Liew D, Butzkueven H on behalf of the MSBase Study Group et al. Fingolimod after natalizumab and the risk of short-term relapse. *Neurology.* 2014 Apr 8;82(14):1204-11. IF 8.2

63 Kalincik T, Vivek V, Jokubaitis V, **Lechner-Scott** J, Trojano M, Izquierdo G, Lugaresi A, Grand'maison F, Hupperts R, Oreja-Guevara C, Bergamaschi R, Iuliano G, Alroughani R, Van Pesch V, Amato MP, Slee M, Verheul F, Fernandez-Bolanos R, Fiol M, Spitaleri DL, Cristiano E, Gray O, Cabrera-Gomez JA, Shaygannejad V, Herbert J, Vucic S, Needham M, Petkovska-Boskova T, Sirbu CA, Duquette P, Girard M, Grammond P, Boz C, Giuliani G, Rio ME, Barnett M, Flechter S, Moore F, Singhal B, Bacile EA, Saladino ML, Shaw C, Skromne E, Poehlau D, Vella N, Spelman T, Liew D, Kilpatrick TJ, Butzkueven H; on behalf of the MSBase Study Group Risk of relapse phenotype recurrence in multiple sclerosis. *Mult Scler.* 2014 Oct;20(11):1511-22.

64 Confavreux C, O'Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky JS, Bagulho T, Delhay JL, Dukovic D, Truffinet P, Kappos L; TOWER Trial Group. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Neurol.* 2014 Mar;13(3):247-56 IF 23.9

65 Goris A, van Setten J, Diekstra F, Ripke S, Patsopoulos NA, Sawcer SJ; International Multiple Sclerosis Genetics Consortium, van Es M; Australia and New Zealand MS Genetics Consortium, Andersen PM, Melki J, Meininger V, Hardiman O, Landers JE, Brown RH Jr, Shatunov A, Leigh N, Al-Chalabi A, Shaw CE, Traynor BJ, Chiò A, Restagno G, Mora G, Ophoff RA, Oksenberg JR, Van Damme P, Compston A, Robberecht W, Dubois B, van den Berg LH, De Jager PL, Veldink JH, de Bakker PI. No evidence for shared genetic basis of common variants in multiple sclerosis and amyotrophic lateral sclerosis. *Hum Mol Genet.* 2014 Apr 1;23(7):1916-22.

66 Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, Hodgkinson S, Kermode AG, **Lechner-Scott** J, Macdonell RA, Marriott M, Mason DF, Parratt J, Reddel SW, Shaw CP, Slee M, Spies J, Taylor BV, Carroll WM, Kilpatrick TJ, King J, McCombe PA, Pollard JD, Willoughby E. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 1 Treatment practicalities and recommendations. *J Clin Neurosci.* 2014 Nov;21(11):

1835-1846.

67 Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, Hodgkinson S, Kermode AG, **Lechner-Scott J**, Macdonell RA, Marriott M, Mason DF, Parratt J, Reddel SW, Shaw CP, Slee M, Spies J, Taylor BV, Carroll WM, Kilpatrick TJ, King J, McCombe PA, Pollard JD, Willoughby E. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 2 Treatment practicalities and recommendations. *J Clin Neurosci*. 2014 Nov;21(11):1847-1856.

68 Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, Hodgkinson S, Kermode AG, **Lechner-Scott J**, Macdonell RA, Marriott M, Mason DF, Parratt J, Reddel SW, Shaw CP, Slee M, Spies J, Taylor BV, Carroll WM, Kilpatrick TJ, King J, McCombe PA, Pollard JD, Willoughby E. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 3 Treatment practicalities and recommendations. *J Clin Neurosci*. 2014 Nov;21(11):1857-1865.

69 Spelman T, Gray O, Trojano M, Petersen T, Izquierdo G, Lugaresi A, Hupperts R, Bergamaschi R, Duquette P, Grammond P, Giuliani G, Boz C, Verheul F, Oreja-Guevara C, Barnett M, Grand'Maison F, Edite Rio M, **Lechner-Scott J**, Van Pesch V, Fernandez Bolanos R, Flechter S, Den Braber-Moerland L, Iuliano G, Amato MP, Slee M, Cristiano E, Saladino ML, Paine M, Vella N, Kasa K, Deri N, Herbert J, Moore F, Petkovska-Boskova T, Alroughani R, Savino A, Shaw C, Vucic S, Santiago V, Bacile EA, Skromne E, Poehlau D, Cabrera-Gomez JA, Lucas R, Butzkueven H. Seasonal variation of relapse rate in multiple sclerosis is latitude dependent. *Ann Neurol*. 2014 Dec;76(6):880-90.

70 Kalincik T, Jokubaitis V, Izquierdo G, Duquette P, Girard M, Grammond P, Lugaresi A, Oreja-Guevara C, Bergamaschi R, Hupperts R, Grand'Maison F, Pucci E, Van Pesch V, Boz C, Iuliano G, Fernandez-Bolanos R, Flechter S, Spitaleri D, Cristiano E, Verheul F, **Lechner-Scott J**, Amato MP, Cabrera-Gomez JA, Saladino ML, Slee M, Moore F, Gray O, Paine M, Barnett M, Havrdova E, Horakova D, Spelman T, Trojano M, Butzkueven H; On behalf of the MSBase Study Group; On behalf of the MSBase Study Group. Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis. *Mult Scler*. 2014 Dec 5

71 Kalincik T, Horakova D, Spelman T, Jokubaitis V, Trojano M, Lugaresi A, Izquierdo G, Rozsa C, Grammond P, Alroughani R, Duquette P, Girard M, Pucci E, **Lechner-Scott J**, Slee M, Fernandez-Bolanos R, Grand'Maison F, Hupperts R, Verheul F, Hodgkinson S, Oreja-Guevara C, Spitaleri D, Barnett M, Terzi M, Bergamaschi R,

McCombe P, Sanchez-Menoyo J, Simo M, Csepány T, Rum G, Boz C, Havrdova E, Butzkueven H; on behalf of the MSBase Study Group. Switch to natalizumab vs fingolimod in active relapsing-remitting multiple sclerosis. *Ann Neurol*. 2015 Mar;77(3):425-35

72 Ribbons KA, McElduff P, Boz C, Trojano M, Izquierdo G, Duquette P, Girard M, Grand'Maison F, Hupperts R, Grammond P, Oreja-Guevara C, Petersen T, Bergamaschi R, Guigliani G, Barnett M, Van Pesch V, Amato MP, Iuliano G, Fiol M, Slee ME, Verheul F, Cristiano E, Fernandez-Bolanos R, Saladino ML, Rio ME, Cabrera-Gomez J, Butzkueven H, van Munster E, Den Braber-Moerland L, Spitaleri DLA, Lugaresi A, Shaygannejad V, Gray O, Deri N, Alroughani R, **Lechner-Scott JS** on behalf of the MSBase Study Group. Male MS patients fare worse. *PLoS One*. 2015 Jun 5;10(6):e0122686.

73 Malhotra S, Río J, Urcelay E, Nurtdinov R, Bustamante MF, Fernández O, Oliver B, Zettl U, Brassat D, Killestein J, **Lechner-Scott J**, Drulovic J, Chan A, Martinelli-Boneschi F, García-Merino A, Montalban X, Comabella M. NLRP3 inflammasome is associated with the response to IFN- β in patients with multiple sclerosis. *Brain*. 2015 Mar;138(Pt 3):644-52

74 Goris A, Pauwels I, Gustavsen MW, van Son B, Hilven K, Bos SD, Celius EG, Berg-Hansen P, Aarseth J, Myhr KM, D'Alfonso S, Barizzone N, Leone MA, Martinelli-Boneschi F, Sorosina M, Liberatore G, Kockum I, Olsson T, Hillert J, Alfredsson L, Bedri SK, Hemmer B, Buck D, Berthele A, Knier B, Biberacher V, van Pesch V, Sindic C, Bang Oturai A, Søndergaard HB, Sellebjerg F, Jensen PE, Comabella M, Montalban X, Pérez-Boza J, Malhotra S, **Lechner-Scott J**, Broadley S, Slee M, Taylor B, Kermode AG, Gourraud PA; International Multiple Sclerosis Genetics Consortium, Sawcer SJ, Andreassen BK, Dubois B, Harbo HF. Genetic variants are major determinants of CSF antibody levels in multiple sclerosis. *Brain*. 2015 Mar;138(Pt 3):632-43

75 He A, Spelman T, Jokubaitis V, Havrdova E, Horakova D, Trojano M, Lugaresi A, Izquierdo G, Grammond P, Duquette P, Girard M, Pucci E, Iuliano G, Alroughani R, Oreja-Guevara C, Fernandez-Bolaños R, Grand'Maison F, Sola P, Spitaleri D, Granella F, Terzi M, **Lechner-Scott J**, Van Pesch V, Hupperts R, Sánchez-Menoyo JL, Hodgkinson S, Rozsa C, Verheul F, Butzkueven H, Kalincik T; for the MSBase Study Group. Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis. *JAMA Neurol*. 2015 Feb 9:1-10.

76 Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, Hodgkinson S, Kermode AG, **Lechner-Scott J**, Macdonell RA, Marriott M, Mason DF, Parratt J,

Reddel SW, Shaw CP, Slee M, Spies J, Taylor BV, Carroll WM, Kilpatrick TJ, King J, McCombe PA, Pollard JD, Willoughby E. McCombe PA, Pollard JD, Willoughby E. A new era in the treatment of multiple sclerosis. Accepted March 2015 mja14.01218.R1

77 Bergamaschi R, Montomoli C, Mallucci G, Lugaresi A, Izquierdo G, Grand'Maison F, Duquette P, Shaygannejad V, Alroughani R, Grammond P, Boz C, Iuliano G, Zwanikken C, Petersen T, **Lechner-Scott** J, Hupperts R, Butzkueven H, Pucci E, Oreja-Guevara C, Cristiano E, Pia Amato MP, Havrdova E, Fernandez-Bolanos R, Spelman T, Trojano M. BREMSO: a simple score to predict early the natural course of multiple sclerosis. *Eur J Neurol.* 2015 Jun;22(6):981-9

78 Jokubaitis, V. G., Spelman, T., Kalincik, T., Izquierdo, G., Grand'Maison, F., Duquette, P., Girard, M., Lugaresi, A., Grammond, P., Hupperts, R., Cabrera-Gomez, J., Oreja-Guevara, C., Boz, C., Giuliani, G., Fernández-Bolaños, R., Iuliano, G., Lechner-Scott, J., Verheul, F., van Pesch, V., Petkovska-Boskova, T., Fiol, M., Moore, F., Cristiano, E., Alroughani, R., Bergamaschi, R., Barnett, M., Slee, M., Vella, N., Herbert, J., Shaw, C., Saladino, M. L., Amato, M. P., Liew, D., Paolicelli, D., Butzkueven, H., Trojano, M. and the MSBasis Study Group (2015), Predictors of disability worsening in clinically isolated syndrome. *Ann Clin Transl Neurol.* 2015 May;2(5):479-91.

79 Spelman T, Kalincik T, Zhang A, Pellegrini F, Wiendl H, Kappos L, Tsvetkova L, Belachew S, Hyde R, Verheul F, Grand-Maison F, Izquierdo G, Grammond P, Duquette P, Lugaresi A, **Lechner-Scott** J, Oreja-Guevara C, Hupperts R, Petersen T, Barnett M, Trojano M, Butzkueven H. Comparative efficacy of switching to natalizumab in active multiple sclerosis. *Ann Clin Transl Neurol.* 2015 Apr;2(4):373-87.

80 Kappos L, D'Souza M, **Lechner-Scott** J, Lienert C. On the origin of Neurostatus. *Mult Scler Relat Disord.* 2015 May;4(3):182-5. doi: 10.1016/j.msard.2015.04.001. Epub 2015 Apr 11

81 Field J, Shahinianian F, Schibeci S; Australia and New Zealand MS Genetics Consortium (**ANZgene**), Johnson L, Gresle M, Laverick L, Parnell G, Stewart G, McKay F, Kilpatrick T, Butzkueven H, Booth D. The MS Risk Allele of CD40 Is Associated with Reduced Cell-Membrane Bound Expression in Antigen Presenting Cells: Implications for Gene Function. *PLoS One.* 2015 Jun 11;10(6):e0127080

82 Gu BJ, Field J, Dutertre S, Ou A, Kilpatrick T, **Lechner-Scott** J, Scott R, Lea R, Taylor BV, Stankovich J, Butzkueven H, Gresle M, Laws SM, Petrou S, Hoffjan S, Akkad DA, Graham CA, Hawkins S, Glaser A, Bedri SK, Hillert J, Matute C, Antiguiedad A; ANZgene Consortium, Wiley JS. A rare P2X7 variant Arg307Gln with absent pore

formation function protects against neuroinflammation in multiple sclerosis. *Hum Mol Genet.* 2015 Oct 1;24(19):5644-54

83 Warrender-Sparkes M, Spelman T, Izquierdo G, Trojano M, Lugaresi A, Grand'Maison F, Havrdova E, Horakova D, Boz C, Oreja-Guevara C, Alroughani R, Iuliano G, Duquette P, Girard M, Terzi M, Hupperts R, Grammond P, Petersen T, Fernandez-Bolaños R, Fiol M, Pucci E, Lechner-Scott J, Verheul F, Cristiano E, Van Pesch V, Petkovska-Boskova T, Moore F, Kister I, Bergamaschi R, Saladino ML, Slee M, Barnett M, Amato MP, Shaw C, Shuey N, Young C, Gray O, Kappos L, Butzkueven H, Kalincik T, Jokubaitis V; **MSBase** study group. The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. *Mult Scler.* 2015 Jul 21.

84 Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, Hodgkinson S, Kermodé AG, **Lechner-Scott J**, Macdonell RA, Marriott M, Mason DF, Parratt J, Reddel SW, Shaw CP, Slee M, Spies JM, Taylor BV, Carroll WM, Kilpatrick TJ, King J, McCombe PA, Pollard JD, Willoughby E. A new era in the treatment of multiple sclerosis. *Med J Aust.* 2015 Aug 3;203(3):139-41

85 Maltby V, Graves M, Lea R, Benton M, Sanders K, Tajouri L, Scott R, Lechner-Scott J. Genome-wide DNA methylation profiling of CD8+ T cells shows a distinct epigenetic signature to CD4+ T cells in multiple sclerosis patients. *Clinical Epigenetics.* 2015, 7:118. DOI: 10.1186/s13148-015-0152-7

86 Macdonell R, Nagels G, Laplaud DA, Pozzilli C, de Jong B, Martins da Silva A, Nicholas R, **Lechner-Scott J**, Gaebler JA, Agarwal S, Wang P, Yeh M, Hovenden M, Soelberg Sørensen P. . Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine. *Mult Scler.* 2015 Oct 7. pii: 1352458515606809

87 Bustamante MF, Morcillo-Suárez C, Malhotra S, Rio J, Leyva L, Fernández O, Zettl UK, Killestein J, Brassat D, García-Merino JA, Sánchez AJ, Urcelay E, Alvarez-Lafuente R, Villar LM, Alvarez-Cermeño JC, Farré X, **Lechner-Scott J**, Vandebroek K, Rodríguez-Antigüedad A, Drulovic JS, Martinelli Boneschi F, Chan A, Oksenberg J, Navarro A, Montalban X, Comabella M. Pharmacogenomic study in patients with multiple sclerosis: Responders and nonresponders to IFN- β . *Neurol Neuroimmunol Neuroinflamm.* 2015 Sep 24;2(5):e154.

88 Kalincik T, Cutter G, Spelman T, Jokubaitis V, Havrdova E, Horakova D, Trojano M, Izquierdo G, Girard M, Duquette P, Prat A, Lugaresi A, Grand'Maison F, Grammond P, Hupperts R, Oreja-Guevara C, Boz C, Pucci E, Bergamaschi R, **Lechner-Scott J**, Alroughani R, Van Pesch V, Iuliano G, Fernandez-Bolaños R, Ramo C, Terzi M, Slee

M, Spitaleri D, Verheul F, Cristiano E, Sánchez-Menoyo JL, Fiol M, Gray O, Cabrera-Gomez JA, Barnett M, Butzkueven H. Defining reliable disability outcomes in multiple sclerosis. *Brain*. 2015 Nov;138(Pt 11):3287-98. doi: 10.1093/brain/awv258. Epub 2015 Sep 10.

89 Collins C, Ivry B, Bowen JD, Cheng EM, Dobson R, Goodin DS, **Lechner-Scott J**, Kappos L, Galea I. A comparative analysis of Patient-Reported Expanded Disability Status Scale tools. *Mult Scler*. 2015 Nov 12. pii: 1352458515616205

90 Field J, Shahijanjan F, Schibeci S; Australia and New Zealand MS Genetics Consortium (ANZgene), Johnson L, Gresle M, Laverick L, Parnell G, Stewart G, McKay F, Kilpatrick T, Butzkueven H, Booth D. The MS Risk Allele of CD40 Is Associated with Reduced Cell-Membrane Bound Expression in Antigen Presenting Cells: Implications for Gene Function. *PLoS One*. 2015 Jun 11;10(6):e0127080

91 Spelman T, Kalincik T, Jokubaitis VG, Zhang A, Pellegrini F, Wiendl H, Belachew S, Lugaresi A, Havrdova E, Horakova D, Grammond P, Duquette P, Prat A, Iuliano G, Terzi M, Izquierdo G, Hupperts RM, Boz C, Pucci E, Giuliani G, Sola P, Spitaleri DLA, Lechner-Scott J, Bergamaschi R, Grand'Maison F, Granella F, Kappos L, Trojano M, Butzkueven H, Hyde R and Verheul F Comparative efficacy of first-line natalizumab versus IFN β or glatiramer acetate in relapsing MS Neurology: Clinical Practice MS ID#: NEURCLINPRACT/2015/010231

92 Binder MD, Fox AD, Merlo D, Johnson LJ et al of the ANZGene group. Common and low frequency variants in *MERTK* are independently associated with Multiple Sclerosis susceptibility with discordant association dependent upon HLA-DRB1*1501 status. PGENETICS-D-15-02507R2

93 Spelman T, Mekhael L, Burke T, Butzkueven H, Hodgkinson S, Havrdova E, Horakova D, Duquette P, Izquierdo G, Grand'Maison F, Grammond P, Barnett M, **Lechner-Scott J**, Alroughani R, Trojano M, Lugaresi A, Granella F, Pucci E, Vucic S; MSBase Study Group. Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis. *Eur J Neurol*. 2016 Apr;23(4):729-36

94 Zhou Y, Zhu G, Charlesworth J, Simpson S, Rubicz R, and ANZgene consortium Genetic loci for Epstein-Barr virus nuclear antigen-1 are associated with risk of multiple sclerosis *Mult Scler* 1352458515626598, January 27, 2016

95 Jokubaitis, Vilija; Spelman, Tim; Kalincik, Tomas; Lorscheider, Johannes; Duquette,

Pierre; Girard, Marc; Prat, Alexandre; Izquierdo, Guillermo; Havrdova, Eva; Horakova, Dana; Grammond, Pierre; Pucci, Eugenio; GrandMaison, Francois; Bergamaschi, Roberto; Van Pesch, Vincent; Granella, Franco; Hupperts, Raymond; Iuliano, Gerardo; La Spitaleri, Daniele; Sola, Patrizia; Boz, cavit; Petersen, Thor; Hodgkinson, Suzanne; McCombe, Pamela; Verheul, Freek; Olascoaga, Javier; Rozsa, Csilla; Lechner-Scott, Jeannette; saladino, maria; Farina, Deborah; Iaffaldano, Pietro; Paolicelli, Damiano; Butzkueven, Helmut; Lugaresi, Alessandra; Trojano, Maria. Predictors of long-term disability accrual in relapse-onset multiple sclerosis. *Ann Neurol.* 2016 Jul;80(1):89-100

96 Lorschneider J, Buzzard K, Jokubaitis V, Spelman T, Havrdova E, Horakova D, Trojano M, Izquierdo G, Girard M, Duquette P, Prat A, Lugaresi A, Grand'Maison F, Grammond P, Hupperts R, Alroughani R, Sola P, Boz C, Terzi M, Pucci E, Lechner-Scott J et al. of the MSBase Study Group. Defining secondary progressive multiple sclerosis. *Brain.* 2016 Sep;139(Pt 9):2395-405.

97 Kister I, Spelman T, Alroughi R, Lechner-Scott J et al. of MSBase study group MS course in patients who stopped disease-modifying therapy v. those who continued on therapy. *J Neurol Neurosurg Psychiatry.* 2016 Oct;87(10):1133-7

98 Mahurkar S, Moldovan M, Suppiah V, Sorosina M, Clarelli F, Liberatore G, Malhotra S, Montalban X, Antigüedad A, Krupa M, Jokubaitis VG, McKay FC, Gatt PN, Fabis-Pedrini MJ, Martinelli V, Comi G, **Lechner-Scott J**, Kermode AG, Slee M, Taylor BV, Vandebroek K, Comabella M, Boneschi FM; Australian and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene), King C. Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study. *Pharmacogenomics J.* 2016 Mar 22. doi: 10.1038/tpj.2016.20

99 Groen K, Maltby VE, Sanders KA, Lechner-Scott J, Tajouri L Erythrocytes in Multiple Sclerosis - Forgotten Contributors to the Pathophysiology? *Multiple Sclerosis Journal Experimental, Translational and Clinical*, 2, 1-9.

100 Ribbons K, Lea R, Schofield PW, Lechner-Scott J. Anxiety levels are a primary psychological predictor of cognitive performance in an Australian MS patient cohort. *J Neuropsychiatry Clin Neurosci.* 2017 Spring;29(2):128-134.

101 Caruana P, Lemmert K, Ribbons R, Lechner-Scott J. Natural killer cell subpopulations differ with multiple sclerosis specific treatments and are correlated with MRI activity. *Mult Scler.* 2016 Nov 1:1352458516679267

102 Sanders KA, Benton MC, Lea RA, Maltby VE, Agland S, Griffin N, Scott RJ, Tajouri

L, **Lechner-Scott**J. Next-generation sequencing reveals broad down-regulation of microRNAs in secondary progressive multiple sclerosis CD4+ T cells. Clin Epigenetics. 2016 Aug 27;8(1):87

103 Tao C, Simpson S, van der Mei I, Blizzard L, Havrdova E, Horakova E, Shaygannejad V, Lugaresi A, Izquierdo G, Trojano M, Duquette P, Girard M, Grand'Maison F, Boz C, Grammond P, Alroughani R, Terzi M, Hupperts R, Oreja-Guevara C, Aidin S, Iuliano G, SolaP, Lechner-Scott J et al of the MSBase Study Group. Higher latitude & lower winter UV significantly predict an earlier age of disease onset in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2016 Dec;87(12):1343-1349

104 Ribbons K, Lea R, Tiedeman C, MacKenzie L, Lechner-Scott J. On-going increase in incidence and prevalence of multiple sclerosis in Newcastle, Australia: a 50-year study. Mult Scler accepted September 2016.

105 Stewart T, Cutter G, Spelman T, Jokubaitis V, Havrdova E, Horakova D, Trojano M, Izquierdo G, Girard M, Duquette P, Prat A, Lugaresi A, Grand'Maison F, Grammond P, Hupperts R, Oreja-Guevara C, Boz C, Pucci E, Bergamaschi R, **Lechner-Scott J**, Alroughani R, Van Pesch V, Iuliano G, Fernandez-Bolaños R, Ramo C, Terzi M, Slee M, Spitaleri D, Verheul F, Cristiano E, Sánchez-Menoyo JL, Fiol M, Gray O, Cabrera-Gomez JA, Barnett M, Butzkueven H., Kalincik T Contribution of different relapse phenotypes to disability in multiple sclerosis. Mult Scler. 2016 Apr 7. pii: 1352458516643392

106 Bateman GA, **Lechner-Scott J**, Lea RA. A comparison between the pathophysiology of multiple sclerosis and normal pressure hydrocephalus: is pulse wave encephalopathy a component of MS? Fluids Barriers CNS. 2016 Sep 22;13(1):18.

107 Simpson S Jr, Tan H, Otahal P, Taylor B, Ponsonby AL, Lucas RM, Blizzard L, Valery PC, **Lechner-Scott J**, Shaw C, Williams D; Ausimmune/AusLong Investigators Group., van der Mei I. Anxiety, depression and fatigue at 5-year review following CNS demyelination. Acta Neurol Scand. 2016 Dec;134(6):403-413.

108 Lizak N, Lugaresi A, Alroughani R, **Lechner-Scott J**, Slee M, Havrdova E, Horakova D, Trojano M, Izquierdo G, Duquette P, Girard M, Prat A, Grammond P, Hupperts R, Grand'Maison F, Sola P, Pucci E, Bergamaschi R, Oreja-Guevara C, Van Pesch V, Ramo C, Spitaleri D, Iuliano G, Boz C, Granella F, Olascoaga J, Verheul F, Rozsa C, Cristiano E, Flechter S, Hodgkinson S, Amato MP, Deri N, Jokubaitis V, Spelman T, Butzkueven H, Kalincik T; MSBase Study Group..

J Neurol Neurosurg Psychiatry. 2016 Sep 28. pii: jnnp-2016-313976. doi: 10.1136/jnnp-2016-313976

109 Odenthal C, Simpson S Jr, Oughton J, van der Mei I, Rose S, Fripp J, Lucas R, Taylor B, Dear K, Ponsonby AL, Coulthard A; Ausimmune AusLong Investigator Groups.. Midsagittal corpus callosum area and conversion to multiple sclerosis after clinically isolated syndrome: A multicentre Australian cohort study. J Med Imaging Radiat Oncol. 2016 Dec 20

110 Spelman T, Meyniel C, Rojas JI, Lugaresi A, Izquierdo G, Grand'Maison F, Boz C, Alroughani R, Havrdova E, Horakova D, Iuliano G, Duquette P, Terzi M, Grammond P, Hupperts R, **Lechner-Scott** J, Oreja-Guevara C, Pucci E, Verheul F, Fiol M, Van Pesch V, Cristiano E, Petersen T, Moore F, Kalincik T, Jokubaitis V, Trojano M, Butzkueven H; MSBasis (an MSBase Substudy) Investigators.. Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice. Mult Scler. 2016 Nov 24. pii: 1352458516679893.

111 Kalincik, T, Lechner-Scott J, Butzkueven H (MSBase study) al. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Lancet Neurol. 2017 Apr;16(4):271-281.

112 Al-Iedani O, **Lechner-Scott** J, Ribbons K, Ramadan S. Fast magnetic resonance spectroscopic imaging techniques in human brain- applications in multiple sclerosis. J Biomed Sci. 2017 Feb 28;24(1):17

113 Ribbons K, Lea R, Tiedeman C, Mackenzie L, **Lechner-Scott** J. Ongoing increase in incidence and prevalence of multiple sclerosis in Newcastle, Australia: A 50-year study. Mult Scler. 2016 Sep 1:1352458516671819

114 Signori A, Izquierdo G, Lugaresi A, Hupperts R, Grand'Maison F, Sola P, Horakova D, Havrdova E, Prat A, Girard M, Duquette P, Boz C, Grammond P, Terzi M, Singhal B, Alroughani R, Petersen T, Ramo C, Oreja-Guevara C, Spitaleri D, Shaygannejad V, Butzkueven H, Kalincik T, Jokubaitis V, Slee M, Fernandez Bolaños R, Sanchez-Menoyo JL, Pucci E, Granella F, **Lechner-Scott** J, Iuliano G, Hughes S, Bergamaschi R, Taylor B, Verheul F, Edite Rio M, Amato MP, Sajedi SA, Majdinasab N, Van Pesch V, Sormani MP, Trojano M. Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. Mult Scler. 2017 Apr 1:1352458517703800. doi: 10.1177/1352458517703800

115 Solis W, G, Waller S, E, Harris A, K, Sugo E, Hansen M, A, Lechner-Scott J, Favourable Outcome in a 33-Year-Old Female with Acute Haemorrhagic Leukoencephalitis. *Case Rep Neurol* 2017;9:106-113.

116 Iaffaldano P, Simone M, Lucisano G, Ghezzi A, Coniglio G, Brescia Morra V, Salemi G, Patti F, Lugaresi A, Izquierdo G, Bergamaschi R, Cabrera-Gomez JA, Pozzilli C, Millefiorini E, Alroughani R, Boz C, Pucci E, Zimatore GB, Sola P, Lus G, Maimone D, Avolio C, Cocco E, Sajedi SA, Costantino G, Duquette P, Shaygannejad V, Petersen T, Fernández Bolaños R, Paolicelli D, Tortorella C, Spelman T, Margari L, Amato MP, Comi G, Butzkueven H, Trojano M; Italian iMedWeb Registry and the MSBase Registry. Prognostic indicators in pediatric clinically isolated syndrome. *Ann Neurol*. 2017 May;81(5):729-739.

117 Bukhari W, Prain KM, Waters P, Woodhall M, O'Gorman CM, Clarke L, Silvestrini RA, Bundell CS, Abernethy D, Bhuta S, Blum S, Boggild M, Boundy K, Brew BJ, Brown M, Brownlee WJ, Butzkueven H, Carroll WM, Chen C, Coulthard A, Dale RC, Das C, Dear K, Fabis-Pedrini MJ, Fulcher D, Gillis D, Hawke S, Heard R, Henderson APD, Heshmat S, Hodgkinson S, Jimenez-Sanchez S, Killpatrick T, King J, Kneebone C, Kornberg AJ, **Lechner-Scott** J, Lin MW, Lynch C, Macdonell R, Mason DF, McCombe PA, Pender MP, Pereira JA, Pollard JD, Reddel SW, Shaw C, Spies J, Stankovich J, Sutton I, Vucic S, Walsh M, Wong RC, Yiu EM, Barnett MH, Kermode AG, Marriott MP, Parratt JDE, Slee M, Taylor BV, Willoughby E, Wilson RJ, Vincent A, Broadley SA. Incidence and prevalence of NMOSD in Australia and New Zealand. *J Neurol Neurosurg Psychiatry*. 2017 May 26. pii: jnnp-2016-314839.

118 Bateman GA, **Lechner-Scott** J, Copping R, Moeskops C, Yap SL. Comparison of the sagittal sinus cross-sectional area between patients with multiple sclerosis, hydrocephalus, intracranial hypertension and spontaneous intracranial hypotension: a surrogate marker of venous transmural pressure? *Fluids Barriers CNS*. 2017 Jul 6;14(1):18.

119 Kalincik T, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, **Lechner-Scott** J, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Solaro C, Grand'Maison F, Hupperts R, Prevost J, Sola P, Ferraro D, Terzi M, Butler E, Slee M, Kermode A, Fabis-Pedrini M, McCombe P, Barnett M, Shaw C, Hodgkinson S, Butzkueven H; MSBase Study Group. Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis. *Mult Scler*. 2017 Aug 1:1352458517728812. doi: 10.1177/1352458517728812.

120 Lorscheider J, Jokubaitis VG, Spelman T, Izquierdo G, Lugaresi A, Havrdova E, Horakova D, Trojano M, Duquette P, Girard M, Prat A, Grand'Maison F, Grammond P, Pucci E, Boz C, Sola P, Ferraro D, Spitaleri D, **Lechner-Scott** J, Terzi M, Van Pesch V, Iuliano G, Bergamaschi R, Ramo-Tello C, Granella F, Oreja-Guevara C, Butzkueven H, Kalincik T; MSBase Study Group. Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. *Neurology*. 2017 Sep 5;89(10):1050-1059. doi: 10.1212/WNL.0000000000004330. Epub 2017 Aug 9.

121 Burnard S, **Lechner-Scott** J, Scott RJ. EBV and MS: Major cause, minor contribution or red-herring? *Mult Scler Relat Disord*. 2017 Aug;16:24-30. doi: 10.1016/j.msard.2017.06.002. Epub 2017 Jun 10

122 Maltby VE, Lea RA, Sanders KA, White N, Benton MC, Scott RJ, **Lechner-Scott** J. Differential methylation at *MHC* in CD4+ T cells is associated with multiple sclerosis independently of *HLA-DRB1*. *Clin Epigenetics*. 2017 Jul 18;9:71. doi: 10.1186/s13148-017-0371-1. eCollection 2017

123 Ramanathan S, Mohammad S, Tantsis E, Nguyen TK, Merheb V, Fung VSC, White OB, Broadley S, **Lechner-Scott** J, Vucic S, Henderson APD, Barnett MH, Reddel SW, Brilot F, Dale RC; Australasian and New Zealand MOG Study Group. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. *J Neurol Neurosurg Psychiatry*. 2017 Nov 15. pii: jnnp-2017-316880

124 Zhou Y, Chen M, Simpson S Jr, Lucas RM, Charlesworth JC, Blackburn N, van der Mei I, Ponsonby AL; Ausimmune/AUSLONG investigators group, Taylor BV. Common genetic variation within miR-146a predicts disease onset and relapse in multiple sclerosis. *Neurol Sci*. 2017 Nov 10. doi: 10.1007/s10072-017-3177-1

125 Malhotra S, Sorosina M, Río J, Peroni S, Midaglia L, Villar LM, Álvarez-Cermeño JC, Schroeder I, Esposito F, Clarelli F, Zettl UK, **Lechner-Scott** J, Spataro N, Navarro A, Comi G, Montalban X, Martinelli-Boneschi F, Comabella M. NLRP3 polymorphisms and response to interferon-beta in multiple sclerosis patients. *Mult Scler*. 2017 Nov 1:1352458517739137.

126 Kalincik T, Manouchehrinia A, Sobisek L, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Izquierdo G, Lugaresi A, Girard M, Prat A, Duquette P, Grammond P, Sola P, Hupperts R, Grand'Maison F, Pucci E, Boz C, Alroughani R, Van Pesch V, **Lechner-Scott** J, Terzi M, Bergamaschi R, Iuliano G, Granella F, Spitaleri D, Shaygannejad V, Oreja-Guevara C, Slee M, Ampapa R, Verheul F, McCombe P, Olascoaga J, Amato MP, Vucic S, Hodgkinson S, Ramo-Tello C, Flechter S, Cristiano E, Rozsa C, Moore F, Luis Sanchez-Menoyo J, Laura Saladino M, Barnett M, Hillert J,

Butzkueven H; MSBase Study Group. Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. *Brain*. 2017 Sep 1;140(9):2426-2443.

127 Kalincik T, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, **Lechner-Scott** J, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Solaro C, Grand'Maison F, Hupperts R, Prevost J, Sola P, Ferraro D, Terzi M, Butler E, Slee M, Kermode A, Fabis-Pedrini M, McCombe P, Barnett M, Shaw C, Hodgkinson S, Butzkueven H; MSBase Study Group. Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis. *Mult Scler*. 2017 Aug 1:1352458517728812.

128 Lorscheider J, Jokubaitis VG, Spelman T, Izquierdo G, Lugaresi A, Havrdova E, Horakova D, Trojano M, Duquette P, Girard M, Prat A, Grand'Maison F, Grammond P, Pucci E, Boz C, Sola P, Ferraro D, Spitaleri D, **Lechner-Scott** J, Terzi M, Van Pesch V, Iuliano G, Bergamaschi R, Ramo-Tello C, Granella F, Oreja-Guevara C, Butzkueven H, Kalincik T; MSBase Study Group. Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. *Neurology*. 2017 Sep 5;89(10):1050-1059.

129 Ramanathan S, Mohammad S, Tantsis E, Nguyen TK, Merheb V, Fung VSC, White OB, Broadley S, **Lechner-Scott** J, Vucic S, Henderson APD, Barnett MH, Reddel SW, Brilot F, Dale RC; Australasian and New Zealand MOG Study Group. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. *J Neurol Neurosurg Psychiatry*. 2018 Feb;89(2):127-137

130 Zhou Y, Chen M, Simpson S Jr, Lucas RM, Charlesworth JC, Blackburn N, van der Mei I, Ponsonby AL; Ausimmune/AUSLONG investigators group, Taylor BV. Common genetic variation within miR-146a predicts disease onset and relapse in multiple sclerosis. *Neurol Sci*. 2018 Feb;39(2):297-304

131 Malhotra S, Sorosina M, Río J, Peroni S, Midaglia L, Villar LM, Álvarez-Cermeño JC, Schroeder I, Esposito F, Clarelli F, Zettl UK, **Lechner-Scott** J, Spataro N, Navarro A, Comi G, Montalban X, Martinelli-Boneschi F, Comabella M. NLRP3 polymorphisms and response to interferon-beta in multiple sclerosis patients. *Mult Scler*. 2017 Nov 1:1352458517739137

132 Groen K, Lea RA, Maltby VE, Scott RJ, **Lechner-Scott** J. Letter to the editor: blood processing and sample storage have negligible effects on methylation. *Clin Epigenetics*. 2018 Feb 14;10:22. doi: 10.1186/s13148-018-0455-6. eCollection 2018

133 Simpson S Jr., van der Mei I, Lucas RM, Ponsonby AL, Broadley S, Blizzard L; Ausimmune/AusLong Investigators Group, Taylor B. Sun Exposure across the Life

Course Significantly Modulates Early Multiple Sclerosis Clinical Course. *Front Neurol.* 2018 Feb 1;9:16. doi: 10.3389/fneur.2018.00016. eCollection 2018

134 Groen K, Maltby VE, Lea RA, Sanders KA, Fink JL, Scott RJ, Tajouri L, **Lechner-Scott J**. Erythrocyte microRNA sequencing reveals differential expression in relapsing-remitting multiple sclerosis. *BMC Med Genomics.* 2018 May 21;11(1):48.

135 Arm J, Al-Iedani O, Quadrelli S, Ribbons K, Lea R, **Lechner-Scott J**, Ramadan S. Reliability of neurometabolite detection with two-dimensional localized correlation spectroscopy at 3T. *J Magn Reson Imaging.* 2018 Apr 23.

136 Kister I, Spelman T, Patti F, Duquette P, Trojano M, Izquierdo G, Lugaresi A, Grammond P, Sola P, Ferraro D, Grand'Maison F, Alroughani R, Terzi M, Boz C, Hupperts R, **Lechner-Scott J**, Kappos L, Pucci E, Hodgkinson S, Solaro C, Butzkueven H. Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy. *J Neurol Sci.* 2018 Aug 15;391:72-76.

137 Hughes J, Jokubaitis V, Lugaresi A, Hupperts R, Izquierdo G, Prat A, Girard M, Duquette P, Grand'Maison F, Grammond P, Sola P, Ferraro D, Ramo-Tello C, Trojano M, Slee M, Shaygannejad V, Boz C, **Lechner-Scott J**, Van Pesch V, Pucci E, Solaro C, Verheul F, Terzi M, Granella F, Spitaleri D, Alroughani R, Jun JK, Fambiatos A, Van der Walt A, Butzkueven H, Kalincik T; MSBase Study Group. Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis. *JAMA Neurol.* 2018 Aug 6.

138 Maltby VE, Lea RA, Ribbons KA, Sanders KA, Kennedy D, Min M, Scott RJ, **Lechner-Scott J**. DNA methylation changes in CD4+ T cells isolated from multiple sclerosis patients on dimethyl fumarate. *Mult Scler J Exp Transl Clin.* 2018 Jul 17;4(3):2055217318787826.

139 Tao C, Simpson S Jr, Taylor BV, Blizzard L, Lucas RM, Ponsonby AL, Broadley S; AusLong/Ausimmune Investigators Group, van der Mei I. Onset Symptoms, Tobacco Smoking, and Progressive-Onset Phenotype Are Associated With a Delayed Onset of Multiple Sclerosis, and Marijuana Use With an Earlier Onset. *Front Neurol.* 2018 Jun 8;9:418.

140 Brown JW, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, Girard M, Duquette P, Trojano M, Lugaresi A, Bergamaschi R, Grammond P, Alroughani R, Hupperts R, McCombe P, Van Pesch V, Sola P, Ferraro D, Grand'Maison F, Terzi M, **Lechner-Scott J**, Flechter S, Slee M, Shaygannejad V, Pucci E, Granella F, Jokubaitis V, Willis M, Rice C, Scolding N, Wilkins A, Pearson OR, Ziemssen T,

Hutchinson M, Harding K, Jones J, McGuigan C, Butzkueven H, Kalincik T, Robertson N; MSBase Study Group. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. *JAMA*. 2019 Jan 15;321(2):175-187

141 Giovannoni G, Hawkes C, Levy M, **Lechner-Scott J**, Waubant E. Should our treatment target in MS include the intrathecal plasma cell response? *Mult Scler Relat Disord*. 2019 Jan;27:A1-A.

142 Kalincik T, Kubala Havrdova E, Horakova D, Izquierdo G, Prat A, Girard M, Duquette P, Grammond P, Onofrij M, Lugaresi A, Ozakbas S, Kappos L, Kuhle J, Terzi M, **Lechner-Scott J**, Boz C, Grand'Maison F, Prevost J, Sola P, Ferraro D, Granella F, Trojano M, Bergamaschi R, Pucci E, Turkoglu R, McCombe PA, Pesch VV, Van Wijmeersch B, Solaro C, Ramo-Tello C, Slee M, Alroughani R, Yamout B, Shaygannejad V, Spitaleri D, Sánchez-Menoyo JL, Ampapa R, Hodgkinson S, Karabudak R, Butler E, Vucic S, Jokubaitis V, Spelman T, Butzkueven H. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. *J Neurol Neurosurg Psychiatry*. 2019 Jan 13. pii: jnnp-2018-319831.

143 Arm J, Al-Iedani O, Lea R, **Lechner-Scott J**, Ramadan S. Diurnal variability of cerebral metabolites in healthy human brain with 2D localized correlation spectroscopy (2D L-COSY). *J Magn Reson Imaging*. 2019 Jan 10. doi: 10.1002/jmri.26642.

144 Nguyen AL, Havrdova EK, Horakova D, Izquierdo G, Kalincik T, van der Walt A, Terzi M, Alroughani R, Duquette P, Girard M, Prat A, Boz C, Sola P, Ferraro D, Lugaresi A, **Lechner-Scott J**, Barnett M, Grand'Maison F, Grammond P, Ramo-Tello C, Turkoglu R, McCombe P, Pucci E, Trojano M, Granella F, Spitaleri D, Van Pesch V, Soysal A, Oreja-Guevara C, Verheul F, Vucic S, Hodgkinson S, Slee M, Ampapa R, Prevost J, Menoyo JLS, Skibina O, Solaro C, Olascoaga J, Shaw C, Madsen KG, Naidoo K, Hyde R, Butzkueven H, Jokubaitis V; MSBase Study Group. Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. *Mult Scler Relat Disord*. 2019 Jan 3;28:235-243.

145 Agland S, Lydon A, Shaw S, Lea R, Mortimer-Jones S, **Lechner-Scott J**. Can a stress management programme reduce stress and improve quality of life in people diagnosed with multiple sclerosis? *Mult Scler J Exp Transl Clin*. 2018 Nov 26;4(4):2055217318813179.

146 Maltby VE, Lea RA, Graves MC, Sanders KA, Benton MC, Tajouri L, Scott RJ, **Lechner-Scott J**. Genome-wide DNA methylation changes in CD19+ B cells from relapsing-remitting multiple sclerosis patients. *Sci Rep*. 2018 Nov 27;8(1):17418.

147 Al-Iedani O, Arm J, Ribbons K, Lea R, **Lechner-Scott J**, Ramadan S. Diurnal stability and long-term repeatability of neurometabolites using single voxel 1H magnetic resonance spectroscopy. *Eur J Radiol*. 2018 Nov;108:107-113.

148 Rhead B, Brorson IS, Berge T, Adams C, Quach H, Moen SM, Berg-Hansen P, Celius EG, Sangurdekar DP, Bronson PG, Lea RA, Burnard S, Maltby VE, Scott RJ, **Lechner-Scott J**, Harbo HF, Bos SD, Barcellos LF. Increased DNA methylation of SLFN12 in CD4+ and CD8+ T cells from multiple sclerosis patients. *PLoS One*. 2018 Oct 31;13(10):e020651.

149 Ahmad H, van der Mei I, Taylor BV, Lucas RM, Ponsonby AL, **Lechner-Scott J**, Dear K, Valery P, Clarke PM, Simpson S, Palmer AJ. Estimation of annual probabilities of changing disability levels in Australians with relapsing-remitting multiple sclerosis. *Mult Scler*. 2018 Oct 23:1352458518806103.

150 Lorscheider J, Kuhle J, Izquierdo G, Lugaresi A, Havrdova E, Horakova D, Hupperts R, Duquette P, Girard M, Prat A, Grand'Maison F, Grammond P, Sola P, Ferraro D, Trojano M, Ramo-Tello C, **Lechner-Scott J**, Pucci E, Solaro C, Slee M, Van Pesch V, Sanchez Menoyo JL, van der Walt A, Butzkueven H, Kappos L, Kalincik T; MSBase Study Group. Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study. *Eur J Neurol*. 2019 Feb;26(2):363-370.

151 Min M, Spelman T, Lugaresi A, Boz C, Spitaleri D, Pucci E, Grand'Maison F, Granella F, Izquierdo G, Butzkueven H, Sanchez-Menoyo JL, Barnett M, Girard M, Trojano M, Grammond P, Duquette P, Sola P, Alroughani R, Hupperts R, Vucic S, Kalincik T, Van Pesch V, **Lechner-Scott J**. Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosis. *Mult Scler*. 2018 Oct;24(12):1569-1577.

152 Ramanathan S, Fraser C, Curnow SR, Ghaly M, Leventer RJ, **Lechner-Scott J**, Henderson A, Reddel S, Dale RC, Brilot F. Uveitis and optic perineuritis in the context of myelin oligodendrocyte glycoprotein antibody seropositivity. *Eur J Neurol*. 2019 Feb 12. doi: 10.1111/ene.13932

Book Chapters

The Audio Recorded Cognitive Screen (ARCS): A flexible and versatile instrument for clinic or research

in Screening Tests: Principles, Analysis and Benefits ID: 2-s2.0-84892116855

Schofield PW, Moore T, Loughland C, **Lechner-Scott J**

111-126. 2013

Invited Lecturers

29.10.94	CMT-Meeting, Zürich
17.03.95	Basler Radiology Meeting, Basel
21.07.95	Med.Genetics Meeting, Lausanne
15.09.95	12.Congress of DGM, Erlangen
28.10.95	CMT- Meeting, Zürich
11.11.95	Basler Meeting for Laboratory Personal, Basel
18.11.95	Seminar of the MS-Society, Kappel, Zürich
21.11.95	Seminar for Nursing Staff, Baden
10.05.96	Dreiländertreffen, Strassbourg
21.04.97	Seminar of the MS-Society, Leuenberg
17.06.97	ENS-Meeting, Rhodes
15.09.06	World Congress of Neurology, Sydney
12.05.07	Tysabri training Sydney
16.06.07	Postgraduate Neurology Meeting, Melbourne
01.11.07	PACTRIMS Taipei, Taiwan
24.07.09	Postgraduate Neurology Meeting, Melbourne
15.05.10	ANZAN, Melbourne
24.07.10	Postgraduate Neurology Meeting, Melbourne
29.05.12	Panasian meeting Kuala Lumpur
14.09.12	PACTRIMS, Beijing, China
20.04.13	Postgraduate Meeting, Sydney
12.05.13	Malaysian Neurology Meeting, Kuala Lumpur
08.03.14	CNS Symposium, Sydney
29.03.14	ANZAN Weekend
19.11.15	PACTRIMS, Seoul, Korea
26.05.16	ANZAN, Perth
18.03.17	CNS Weekend, Sydney
24.11.17	PACTRIMS, Ho Chi Minh City, Vietnam
31.08.18	ISNI, Brisbane, Australia

Conference Host

24-25th of August 2018

Immunology Crossroads
Interdisciplinary conference

Teaching experience

Seminars for intensive care

Seminars for physiotherapists

Tutorials for medical students at the University of Freiburg (D) and Basel (CH)

EDSS-Training for neurologists (EU)

Lectures for medical students Year 2 at the University of Newcastle

Teaching Professional Skills for Neurology, University of Newcastle

Examiner for Year 5, University of Newcastle

Teaching rounds for FRACP candidates

FRACP examiner